RESEARCH

Left atrial function during exercise stress echocardiography as a sign of paroxysmal/ persistent atrial fibrillation

Angela Zagatina^{1*}, Quirino Ciampi², Jesus Vazquez Peteiro³, Elena Kalinina¹, Irina Begidova¹, Ratnasari Padang⁴, Alla Boshchenko⁵, Elisa Merli⁶, Matteo Lisi⁷, Hugo Rodriguez-Zanella⁸, Sergio Kobal⁹, Gergely Agoston¹⁰, Albert Varga¹⁰, Karina Wierzbowska-Drabik¹¹, Jarosław D. Kasprzak¹², Rosina Arbucci¹³, Olga Zhuravleva⁵, Jelena Čelutkienė¹⁴, Jorge Lowenstein¹³, Nithima Chaowalit Ratanasit¹⁵, Paolo Colonna¹⁶, Scipione Carerj¹⁷, Mauro Pepi¹⁸, Patricia A. Pellikka⁴, Eugenio Picano¹⁹ and on behalf of the Stress Echo 2030 study group

Abstract

Objective Atrial cardiomyopathy is closely associated with atrial fibrillation (AF), and some patients exhibit no dysfunction at rest but demonstrate evident changes in left atrial (LA) function and LA volume during exercise. This study aimed to identify distinguishing signs during exercise stress echocardiography (ESE) among patients in sinus rhythm (SR), with and without history of paroxysmal/persistent AF (PAF).

Methods A prospective cohort of 1055 patients in SR was enrolled across 12 centers. The main study cohort was divided into two groups: the modeling group (n = 513) and the verification group (n = 542). All patients underwent ESE, which included B-lines, LA volume index (LAVi), and LA strain of the reservoir phase (LASr).

Results Age, resting and stress LAVi and LASr, and B-lines were identified as a combination of detectors for PAF in both groups. In the entire cohort, aside from resting and stress LAVi and LASr, additional parameters differentiating PAF and non-PAF patients were the presence of systemic hypertension, exercise E/e' > 7, worse right ventricle (RV) contraction during exercise (Δ tricuspid annular plane systolic excursion < 5 mm), a lower left ventricular contractile reserve (< 1.6), and a reduced chronotropic reserve (heart rate reserve < 1.64). The composite score, summing all 9 items, yielded a score of >4 as the best sensitivity (79%) and specificity (65%).

Conclusion ESE can complement rest echocardiography in the identification of previous PAF in patients with SR through the evaluation of LA functional reservoir and volume reserve, LV chronotropic, diastolic, and systolic reserve, and RV contractile reserve.

Keywords Atrial fibrillation, B-lines, Left atrium, Reservoir strain, Exercise stress echo

*Correspondence: Angela Zagatina zag_angel@yahoo.com Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.



Open Access

Graphical Abstract

A scoring system predicting the probability of PAF. The score was computed using the cutoff values as in the illustration. The score >4 demonstrated a sensitivity of 79% and a specificity of 65% of PAF.



Background

Atrial fibrillation (AF) is the most prevalent atrial tachyarrhythmia, affecting an estimated 2% to 4% of adults worldwide, excluding those with asymptomatic forms of the disease [1]. AF is a well-recognized and treatable risk factor for stroke, but it often remains asymptomatic or subclinical, leading to underdiagnosis. It is noteworthy that approximately 25% of cryptogenic strokes are attributed to asymptomatic AF, highlighting the substantial thromboembolic risk associated with this condition [2].

The pathogenesis of AF is believed to be closely linked to structural and functional changes in the atria, which fall under the newly proposed concept of "atrial cardiomyopathy" [3, 4]. Excessive tension in the wall of the left atrium (LA) is thought to be responsible for mechanical and structural remodeling, resulting in the replacement of muscle fibers with connective tissue. This increased tension and reduced muscle fibers ultimately lead to impaired LA functional reserve.

Two-dimensional (2D) strain imaging of the LA is an innovative echocardiographic parameter that holds the potential for early AF detection. In particular, the LA strain of the reservoir phase (LASr) is informative and highly reproducible, therefore suitable for a multicenter study [5, 6]. Our hypothesis is that patients with paroxvsmal/persistent AF may not exhibit LA dysfunction at rest, yet they may display evidence of LA functional changes and LA volume alterations during exercise. Patients with permanent AF tend to have more pronounced LA impairment, but given their arrhythmia, they typically receive appropriate treatment for stroke prevention without additional diagnostic methods. These stress atrial markers can be useful in the early identification of atrial cardiomyopathy and incipient rhythm disturbances, showing persistent functional abnormalities in patients with previous AF history despite current SR.

The aim of this study was to identify distinguishing signs during exercise stress echo (ESE) between patients

in sinus rhythm (SR) with and without history of paroxysmal/persistent AF (PAF).

Methods

A prospective cohort of 1146 consecutive patients was initially considered from 12 cardiology institutions in 11 countries. These patients were referred for clinicallydriven ESE as part of the Stress Echo 2020-2030 study network [7, 8]. Recruitment occurred between November 2020 and February 2024. The patients were referred for ESE due to conditions such as heart failure and/or chronic coronary syndromes (CCS).

Inclusion criteria encompassed patients aged over 18 years who underwent an analysis of LA function during ESE, including the assessment of LA volume index (LAVI) and LASr. Exclusion criteria comprised the presence of AF during the test, including permanent AF, as well as severe valvular or congenital heart disease or LA views of inadequate image quality.

The main study cohort was subdivided into two groups: the modeling group and the verification group. All consecutive patients in whom LASr assessment was feasible at rest from November 2020 until July 2022 were included in the modeling group. Subsequently, all consecutive patients with feasible LASr assessment from August 2022 until February 2024 were included in the verification group. Data from patients in the modeling group were utilized to develop a formula for detecting PAF. The verification group was established to assess the formula's significance for independent "all-comer" patients. The study protocol was reviewed and approved by the institutional ethics committees, as a part of the more comprehensive stress echo 2020 study (Clinical trials.Gov Identifier NCT 030.49995) and stress echo 2030 study (Clinical trials. Gov Identifier NCT 050.81115) [9].

Echocardiography

Transthoracic echocardiography (TTE) was performed using commercially available ultrasound machines equipped with multifrequency phased-array sector scan probes and second harmonic technology. All patients underwent comprehensive TTE at rest. All measurements were taken by certified cardiologists according to the current recommendations [10].

Stress echocardiography

All patients underwent comprehensive ESE with the ABCDE+protocol [11]. There were two types of exercise tests: semi-supine bike and post-treadmill. Loops for wall motion, contractile reserve, and LASr analysis were obtained immediately at peak stress and post-stress, as soon as possible, up to 1.5 min. The B-lines, diastolic function parameters were obtained till 3 min after

exercise. Regional wall motion abnormalities (RWMA), B-lines, and when possible, coronary flow velocity reserve in the mid-distal left anterior descending artery were assessed. Wall motion score index (WMSI) was calculated in each patient at baseline and peak stress, in a four-point score ranging from 1 (normal) to 4 (dyskinetic) in a 17-segment model of the LV [12]. B-lines were evaluated with a simplified 4-site scan in the third intercostal space, between mid-axillary to anterior axillary and anterior axillary to mid-clavicular lines, each space scored from 0 (normal horizontal A-lines) to 10 (white lung), with a cumulative score per patient from 0 (normal) to 40 (severely abnormal). The stress-rest change in B-lines was Δ B-lines, with higher values indicating more pulmonary congestion during stress. Left ventricle (LV) contractile reserve was assessed as the stress/ rest ratio of force, calculated as systolic blood pressure/ end-systolic volume. Coronary flow velocity reserve was assessed during the standard SE examination using intermittent imaging of wall motion and left anterior descending artery. HRR was calculated as the peak/rest heart rate from a 12-lead electrocardiogram (ECG). The procedure of acquisition was standardized between centers through a web-based learning module before starting data collection. All readers (one for each center) underwent quality control as previously described [13, 14].

Additionally, we conducted assessments of several cardiac parameters at rest and peak or immediately post-ESE. These included LV ejection fraction (EF), LV end-diastolic volume, E/e', pulmonary artery systolic pressure estimation, and the so-called step L for LA: LAVi and LASr. Continuous ECG monitoring was used throughout the test, and blood pressure measurements were taken at each stage. The criteria for interrupting the test included the following conditions: severe chest pain, diagnostic ST-segment abnormalities, excessive blood pressure increase (systolic blood pressure \geq 240 mmHg, diastolic blood pressure \geq 120 mmHg), achievement of >85% of target HR, muscular exhaustion, and significant arrhythmias [15].

LA assessment

LAVI was measured from apical 4- and 2-chamber views using the modified method of disks and indexed for the body surface area. LASr was measured by speckle-tracking echocardiography using frame rates from 40 to 80/s. The speckle tracking technique is a postprocessing algorithm that quantifies LA deformation by tracking the motion of speckles within the whole myocardium through the cardiac cycle. The LASr was calculated from either an apical 4-chamber view (average from 6 LA segments) or combined 4- and 2-chamber views (average value from 12 LA segments) according to recommendations [16]. In each patient, the same approach (single apical or biplane views) was used at rest and peak ESE. LASr was calculated at LV-end diastole, with the QRS beginning as the zero-reference time point used as a surrogate of end-diastole. The first positive peak corresponds to the LA reservoir phase, and values are expressed as percentage points, algebraically positive (Fig. 1). Both LAVi and LASr were measured using offline echocardiography software from the rest and peak/near peak loops. All measurements were conducted by the sonographers without prior knowledge of the objective of this study.

Statistical analysis. In the presentation of data, we used the following formats as appropriate: mean ± standard deviation (SD) for normally distributed continuous variables; number (percentage) for categorical variables; median (interquartile range) for skewed continuous variables. To assess the distribution of the data, we conducted a Kolmogorov-Smirnov test. Group differences were analyzed depending on the type of data: Student's t-test for normally distributed continuous variables, ANOVA for normally distributed continuous variables with multiple groups, Kruskal-Wallis test for skewed continuous variables with multiple groups; Chisquare or Fisher exact tests for categorical variables. In the modeling group, logistic regression was employed to create a detecting formula. The "enter" method was used, with variables included if they had a significance level (p-value) of < 0.1. Receiver operating characteristic (ROC) analysis was conducted to determine the cutoff values of prognostic discriminators in the modeling group and to assess their accuracy in predicting outcomes in the verification group. A probability value < 0.05 was considered statistically significant in all analyses. The Statistica package version 10.0 (Stat Soft Inc., Tulsa, Oklahoma, USA) and MedCalc Statistical Software version 14.8.1 (MedCalc Software bvba, Ostend, Belgium) were used for statistical analysis.

Results

Rest LAVI and LASr parameters were obtained in all patients, by selection. The study population consisted of 935 patients without a history of PAF, 120 with paroxysmal/persistent AF, and 91 with permanent AF. A total of 91 patients were excluded from the study due to the presence of AF during the test, including those with



Fig. 1 Example of LAVI and LASr measurement

permanent AF. The bike tests were performed on 678 patients (64%), the treadmill tests were conducted in 377 patients (36%). Extrasystolic beats were recorded in 423 patients (40%), of whom 73 (7%) had bigeminy, and 47 patients (4.5%) experienced supraventricular tachycardia during exercise.

There were 44 patients (4%) with moderate mitral regurgitation, 368 patients (38%) with mild to trivial mitral regurgitation, and the majority of the remaining patients had no mitral regurgitation.

The modeling group comprised 513 patients, while the verification group consisted of 542 patients. The baseline clinical characteristics, echocardiography, and ESE data are summarized in Table 1.

Within the modeling group, patients were further divided into subgroups based on the presence or absence of PAF. The key differences between these subgroups are presented in Table 2. Patients with PAF showed more prevalent systemic hypertension compared to patients in SR without a history of AF. In patients with PAF, TTE showed a larger LAVI (at rest and during exercise), reduced LASr (limited/absence of functional reserve during exercise), higher E wave velocity, and lower HRR, indicative of a reduced cardiac sympathetic reserve and cardiac autonomic imbalance.

The differences in LA sizes and function during exercise for the entire study cohort are presented in Table 3.

LAVi during exercise did not significantly change in either group (p = 0.43 for one group and p = 0.85 for the other). LASr during exercise significantly increased in patients without a history of PAF (p < 0.000001), whereas it did not change significantly in patients with a history of PAF (p = 0.06).

There was no significant correlation between LASr at rest and B-lines at rest (r=-0.06, p=0.06). However, there were mild but significant correlations between LASr at rest and exercise B-lines (r=-0.15, p<0.0001), and between exercise LASr and exercise B-lines (r=-0.18, p<0.0001).

Logistic Regression analysis

Logistic regression analysis resulted in the creation of a predictive model for PAF that exhibited a high level of statistical significance (p-value < 0.0001). The coefficients and constant for this formula are provided in Table 4.

The formula generated from logistic regression analysis achieved a classification accuracy of 91.6%, correctly identifying cases in the modeling group. The discriminator was > 0.0893. The ROC analysis showed an area under the curve (AUC) of 0.78, with a highly significant *p*-value of < 0.0001, as illustrated in Fig. 2.

In the verification group, this predictive formula also demonstrated significant discriminative capabilities for PAF, with a sensitivity of 49% and specificity of 79%. The AUC in the verification group was 0.67, indicating a meaningful discriminatory power (*p*-value < 0.0001).

ROC-analysis for PAF prediction

For easier clinical application, a simplified scoring system was created to predict the probability of PAF. This scoring system is constructed using the variables that better differentiate the two groups (those with and without PAF) in the overall patient population, combining the modeling and verification groups (as shown in Table 5). The score was computed using the cutoff values. This system enables clinicians to evaluate the likelihood of PAF in patients based on these defined criteria.

The ROC analysis of the scoring model using the entire cohort showed an AUC of 0.77, indicating a high ability to distinguish between patients with and without PAF (p-value < 0.0001). This scoring system demonstrated a sensitivity of 79% and a specificity of 65%. A higher score indicates a greater likelihood of PAF, as evidenced by a Chi-squared test for trend (p < 0.0001). Notably, the use of this score proved significantly more accurate compared to relying solely on the known increase in LAVi at rest in the main cohort (p < 0.003), as depicted in Fig. 3. Among the parameters, E/e' and stress-rest variation of tricuspid annular plane systolic excursion (Δ TAPSE) were less frequently obtained during SE, resulting in a patient group of 474. The model utilizing 7 parameters, excluding E/e' and Δ TAPSE, also yielded high accuracy in detecting PAF. If the score exceeded 3, the AUC of the ROC curve was 0.73 (*p*-value < 0.0001), with a sensitivity of 66% and a specificity of 69%.

Two hundred thirty-eight patients comprised two matched groups. The average age was 67.9 ± 9.6 years in one group and 67.9 ± 9.7 years in the other (p = 0.996). There were no significant differences in the distribution of sex, diabetes mellitus, hypertension, or ischemia between the groups. Only LAVi and LASR at rest and during stress showed statistically significant differences among all the echocardiography and stress echocardiography parameters (Table 6). Additionally, Scores 9 and 7 differed significantly between the groups (p < 0.000005 for both comparisons).

Discussion

We evaluated a cohort consisting of 1055 patients in SR during ESE aiming to find distinguishing signs of those having PAF. This evaluation covered the assessment of LA morphology (using LAVI) and function (using LASr), as well as B-lines and HRR. The results suggest that this comprehensive method is practical and informative.

Not surprisingly, a history of PAF was associated with advanced age and a high prevalence of systemic

Table 1 Clinical, echocardiographic and stress echo findings in the study population

App 643 + 11.1 6.3 + 12.6 0.007 Mid/fende 315/198 207/211 0.014 Prior PAF 50 (07%) 70 (12.9%) 0.128 Body maximdex, kg/m² 244 (55.0.307) 77.3 (44-50.1) 0.001 Hypartansion 75% 75% 0.38 0.011 Hypartansion 75% 75% 0.393 0.037 Diaberes 19% 10% 0.06 0.037 Obestry 33% 26% 0.014 Pior MI 21% 15% 0.0006 Pior MI 21% 16% 0.0006 Pior MI 21% 16% 0.0006 Pior MI 21% 70 (52.4%) 0.0006 Stratuming 130 (116-145) 128 (120-138) 0.0009 Stratuming 0.0042/8 70 (52.4%) 0.0000 0.0026 Mid (ndm² 9.01 (64-10.6%) 80 (70-8%) 0.0001 0.0010 0.0010 0.0010 0.0010 0.0010 0.0010 0.0010		Modeling group N=513	Verification group <i>N</i> =542	p
Maleformale15/19820/12/51014Phor NAF50(778)70(1278)1128Body mass index, kg/m²244 (25-307)273 (24-51)10.003Body mass index, kg/m²144 ±0221284 0.210.001Body mass index, kg/m²7%7%0.993Dabers19%10%0.993Dabers19%10%0.993Dabers19%10%0.993Dabers19%20%0.993Doking20%10%0.004Pior NC7%0.0070.993Dipore NCHA7062-78110%0.006Dipore NCHA7062-7810.0070.005Pior NC0.001/764-107128 (120-138)0.001Dipore NCHA0.002 (764-1078)0.0020.998RMT0.017 (764-1078)805 (74-108)0.002RMT0.017 (764-1078)95 (76-103)0.002RMT0.026 (74-108)805 (74-108)0.001LEV ext, ml31 (55-104)85 (56-102)0.002LEV ext, ml31 (55-104)85 (56-102)0.002LEV ext, ml31 (55-104)85 (56-102)0.002LEV ext, ml12 (14-020)12 (14-02)0.002LEV ext, ml12 (14-020)	Age	64.3±11.1	62.3±12.6	0.007
Pinr Mri20 (0.7%)20 (0.7%)0.12Body mass index, kg/m²28 (0.20-307)273 (246-30.1)0.001Body undex ene, m²144-1221.88-0.210.001Hypertension7%7%0.890.60Diabetas19%16%0.252Smaking10%16%0.252Smaking10%16%0.002Diabetas17%26%0.004Pinr M21%18%0.002Pinr ML21%16%0.002Pinr ML21%11-210.005Pinr ML21%11.210.005SP est, minhig0.0118-145128.122-1300.009Binr Mri0.010-141/050.670-421-0500.009SP est, minhig0.010-141/050.670-421-0500.002Finrt, minhig0.010-141/050.43.002-0490.002Er est, minhig0.010-141/050.642-10500.002Er est, minhig0.010-141/050.642-10500.002Er est, minhig0.010-1610.43.002-0490.002Er est, minhig0.010-1610.43.002-040.002Er est, minhig0.010-1610.010-010.020Di Er est, minhig0.010-1610.010-010.020Di Er est, minhig0.010-01-010.0200.020Di Er est, minhig0.010-01-010.0200.020Di Er est, minhig0.010-01-010.0200.020Di Er est, minhig0.010-01-010.0200.020Di	Male/female	315/198	291/251	0.014
backy maxim dax, kg/m²244 (20-30.7)247 (24.46.30.1)0.003Body surface arcs, m²194 40.22188 ±0.210.001Hypertamion1%16%0.252Snoking10%16%0.023Debets3%0.060.014Pior MI21%1%0.008Pior PC7%1%0.0008Deprior PC7%16.27%0.0008Dypena NIM Class21%7.062-780.0026Depres, mmHg0.0170.4107.0185.074.2108.010.009SBP rest, mmHg0.0170.4107.0185.074.2108.010.009Brest, mmHg0.0170.4107.0185.074.2108.010.002MM, g/m²0.0170.4107.0185.074.2108.010.002Frest, mmHg0.403.074.0480.0104.010.002Exet, mrN40.401.07.048.010.0102.010.002LCDV rest, mi83.05.10.210.0020.001LCDV rest, mi83.05.10.210.0010.002LCDV rest, mi1.001.00.10.010.0260.001LCDV rest, mi1.021.02.10.011.001.00.10.010.026LSDV rest, mi1.021.02.10.011.001.02.10.010.001LSP rest, mi/m²2.02.13.110.0210.001LSP rest, mi/m²2.02.13.110.0210.001LSP rest, mi/m²0.061.010.010.01.01.010.026LSDV rest, mi/m²0.061.010.010.01.01.010.026LSDV rest, mi/m²0.061.010.010.01.01.010.010LSP rest,	Prior PAF	50 (9.7%)	70 (12.9%)	0.128
Body surface area, m²1044-022188+0210001Hypertension75%75%0039Hypertension10%16%0232Sinoking10%10%073Obesity35%75%014Plor PL24%13%0008Plor PL26%16%0008Plor PL26%16%0008Signes Intrifug01(2-278)70(2-78)0092Signes Intrifug00.764/05.0046406.0026Bet ext, mmHg00.764/05.0045(3-74.0)0593RVT01.764/107.6045(3-74.0)0593RVT01.764/107.6045(3-74.0)0593RVT01.764/107.6045(3-74.0)0593RVT01.764/107.6045(3-74.0)0593RVT01.764/107.6045(3-74.0)0502RVT01.764/107.6045(3-74.0)0502RVT01.764/107.6045(3-74.0)0502RVT01.764/107.6045(3-74.0)0502RVT01.764/107.6045(3-74.0)0502RVT01.764/107.6045(3-74.0)0501LVEDV rest, ml04.751.204.000501LVEF st rest, fill10.761.204.000501LVEF st rest, fill10.761.204.000502LVEF st rest, fill10.251.205230523LVEF st rest, fill25.147.702020501LVEF st rest, fill10.361.605040504LVEF st rest, fill10.16	Body mass index, kg/m ²	28.4 (25.0-30.7)	27.3 (24.6-30.1)	0.003
Hypertension75%75%9399Diebets19%16%0.232Sonking10%16%0.232Obesity33%26%0.014Phor PC21%15%0.0088Phor PC20%18%0.0068Dypene NYHA Class21%16/27.010.0068Byrest, mmHg00162-67.0126/27.010.006BWT001764-107.0185/CF42-108.010.009DBP est, mmHg001764-107.0185/CF42-108.010.009RWT0.470.470.6185/CF42-108.010.001Fest, cm/s0.976-8619.576.11.510.002Fest, cm/s83/GF-10385/GF41.010.001Fest, cm/s83/GF-10385/GF41.010.001VEDV rest, ml0.476.57.0185/GF41.010.001VEDV rest, ml0.476.57.0185/GF41.010.001VEDV rest, ml0.476.57.010.0220.002VMS rest10.010.01.000.0010.0010.001VESV rest, ml0.010.01.000.0010.002VMS rest10.010.01.000.0010.0010.002VESV rest, ml0.010.01.000.0010.0010.001VESV rest, ml0.010.01.000.0010.0010.001VESV rest, ml0.010.01.010.0010.0010.001VESV rest, ml0.010.01.010.0010.0010.001VESV rest, ml0.010.01.010.0010.0010.001VESV rest, ml0.010.01	Body surface area, m ²	1.94±0.22	1.88±0.21	0.001
Dabets19%16%0.252Smoking10%10%0.973Obesity33%26%0.014Pior M21%13%0.0008Pior PC26%13%0.0008Dypneal NPIA Class21.7111.720.0006Hif rest, beats/min70.62.7870.62.780.002DBP rest, mmHg80.070-9080.070-900.026DBM rest, mmHg0.01.64.107.610.43.070-4910.026DMM, dm²0.02.070-910.43.070-4910.0001Piest, cms/s0.02.070-4910.43.070-4910.0001Piest, cms/s0.90.74.1050.43.070-4910.0001Piest, cms/s30.65.10.418.3.65.10.210.0001Piest, cms/s30.42.65.013.02.44-010.0001UESY rest, min34.02.50.013.02.04-010.0001UESY rest, min3.0.65.10.210.00010.001UESY rest, min3.0.65.10.210.00010.001UESY rest, min3.0.65.10.210.00010.001UESY rest, min2.0.21.072.0.22.010.001LAT rest, significati1.00.10.01.000.0010.001UESY rest, min2.0.21.011.00.01.01.010.001LAT rest, significati3.0.11.61.42.113.0.01.01.010.001LAT rest, significati3.0.11.61.42.110.0010.001LAT rest, significati3.0.11.61.42.110.001.01.010.001LAT rest, mmHg8.0.61.000.0010.001L	Hypertension	75%	75%	0.939
Smoking10%10%0973Obesity33%26%014Obesity33%26%010Pior MI21%13%0000Pior MI21%11(-2)0008Dyspnea NYHA Class2(1-2)0005BP rest, mmHg10016-7/8)10(62-78)0005SP rest, mmHg30(16-107.6)80(70-86)0026DBP rest, mmHg001076-107.6)805 (04.210.98)0029RWT04(3.37-04.90)04303.37-04.900001eff rest, cm/s70 (58-84)5(6-80)00001eff rest, cm/s89 (74-10.5)80 (70-80)0001eff rest, cm/s89 (74-10.5)85 (51-07)0001VEDV vest, mI44 (25-132)85 (61-07)0001VEDV vest, mI34 (26-50)30 (24-40)0001VEDV vest, mI100 (10.51-00)100 (10.51-00)0001VEDV vest, mI100 (10.51-00)100 (10.51-00)0001 <tr< td=""><td>Diabetes</td><td>19%</td><td>16%</td><td>0.252</td></tr<>	Diabetes	19%	16%	0.252
Obesity33%20%0.014Piror PC7%13%0.000Dyspnas NVIA Class21/-2)11/-2)0.000HR est, best/min70 (62-78)70 (62-78)0.000DBP rest, mmHg130 (118-145)123 (120-138)0.000DBP rest, mmHg130 (116-145)81 (70-90)0.026NMA g/m²0.01 (76A-107.6)896 (742-109.8)0.000PR rest, cm/s0.02 (03-70.48)0.42 (03-70.48)0.0001e'rest, cm/s0.02 (03-70.48)0.65 (-12)0.001e'rest, cm/s89 (74-10.5)0.0020.001e'rest, cm/s89 (74-10.5)0.0020.001e'rest, cm/s80 (74-10.5)0.0020.001VESV rest, ml44 (26-50)35 (26-10.7)0.002VESV rest, ml10.10.01.00.100.0260.001VESV rest, fls10.66 (64-67)0.76 (83-10.7)0.002VESV rest, fls25 (21-31)22 (0-25)0.001LAST rest, fls25 (21-31)22 (0-25)0.001LAST rest, fls25 (21-31)25 (21-31)0.010LAST rest, fls10.01.04-10.0010.020.026LAST rest, fls10.01.64-02)27 (64-93)0.001LAST rest, fls10.01.64-02)26 (21-31)0.010LAST rest, fls10.01.64-02)10.01.61-1330.001LAST rest, fls10.01.64-02)10.01.61-1330.001LAST rest, fls10.01.64-02)10.01.61-1330.001LAST rest, fls10.0	Smoking	10%	10%	0.973
Prior MI21%13%0.0008Prior PCD26%18%0.0008Prior PCD21-1211-120.0008HR red, boats/min20 (27.9)10 (27.9)0.0005SBP rest, mmHg0.0018-145)128 (120-138)0.0026DBP rest, mmHg0.00260.0260.026IMM, g/m20.0176-4-107.6)89.6 (74.9-109.8)0.026IMM, g/m20.026 (37.94.9)0.0360.036Rest, cmV30.026 (37.94.9)0.0300.036Fest, cmV30.026 (37.94.9)0.00010.0001e fest, cmV383 (5.9-10.4)85 (56-10.7)0.0001LEPZ vest, mI44 (75-123)85 (58-10.7)0.0001LEPZ vest, mI0.001.00-1.06)0.010.00-1.000.001LEPZ vest, mI1.00 (1.00-1.06)1.00 (1.00-1.00)0.001LEPZ vest, mI22 (12.9)27.64.9.30.0001LEPZ vest, mI/m222 (2.3-13.1)22 (2.3-13.1)0.001LAPS rest, m/m30.011-0.421.00 (1.00-1.00)0.020.001LAPS rest, m/m330 (15-13.2)1.01 (15-13.4)0.01LAD levy rest, fm409, cm/s25 (2.3-13.1)26 (2.3-13.1)0.01LAD levy rest, fm409, cm/s36 (2.5-10.2)0.0010.02LAD levy rest, fm409, cm/s36 (2.5-10.2)0.0010.02LAD levy rest, fm409, cm/s36 (2.5-10.2)0.0010.02LAD levy rest, fm4041.50 (5.1-30.1)0.0010.02LAD levy rest, fm40436 (2.5-10.2) <td< td=""><td>Obesity</td><td>33%</td><td>26%</td><td>0.014</td></td<>	Obesity	33%	26%	0.014
Phor PCI26%1%%0006Dyspnes NYHA Class2(1-2)1(1-2)0006BY rest, beats/min70(62-78)70(62-78)0009SBP rest, mmHg30(178-145)128 (120-138)0009DBP rest, mmHg001 (76-107.0)85 (742-108.3)0559RVT0.42 (0.37-0.48)0.43 (0.37-0.49)0009E rest, cm/s0.42 (0.37-0.48)0.57 (63-15)0002E rest, cm/s8.8 (74-105)8.5 (76-115)0002E rest, cm/s8.8 (58-10.4)8.5 (58-10.2)0.0001E rest, cm/s8.6 (56-46.7)8.5 (58-10.2)0.0001UESV rest, mI0.4 (10-10.6)1.00 (1.00-10.0)0.26C SL V rest, %1.00 (1.00-1.06)1.00 (1.00-10.0)0.26C SL V rest, %1.25 (1-27.2)2.202.5)0.0001LAS rest, %2.5 (1-27.3)2.2 (2-25.0)0.001LAS rest, [%]7.2 (14.0-20.0)1.00 (1.00-1.04.2)0.021LAS rest, [%]2.5 (1-31)0.0210.021LAS rest, [%]1.30 (1.16-12)0.101 (1.5-14.3)0.001LAS rest, [%]1.30 (1.5-14.2)0.0010.021LAS rest, [%]1.30 (1.5-15.2)1.50 (5-14.0)0.002LAS rest, mmHg1.50 (5-10.0)0.0020.002LSS stress, m12.61 (1-37.3)0.0010.001LSS stress, m13.01 (1.5-12.2)1.50 (5-14.0)0.001LSS stress, m12.61 (1-30.3)0.6100.002LSS stress, m12.61 (1-37.3)0.001 <td>Prior MI</td> <td>21%</td> <td>13%</td> <td>0.0008</td>	Prior MI	21%	13%	0.0008
Dyspnen NYHA Class2 (1-2)1 (1-2)0.0006Hill rest, beatx/min70 (62-78)70 (62-78)0.009DBP rest, mmHg130 (118-145)180 (120-138)0.009DBP rest, mmHg80 (70-90)80 (70-96)0.026MM, dym'0.10 (64-107.6)88 (612-108)0.998Enst, cm/s0.42 (037-048)0.43 (037-049)0.998Enst, cm/s70 (58-84)75 (63-89)0.0001e' rest, cm/s83 (65-104,083 (65-102,00.0001e' rest, cm/s83 (65-104,083 (65-102,00.0001LVEDV rest, ml44 (75-123)83 (63-102,00.0001UVEDV rest, ml44 (75-123,00.001 (100-100,00.026GLS LIV rest, 16[17.2 (14.0-200,017.0 (14.5-192,00.001LAS rest, 16[27.54 9.222 (20-25)0.001LAS rest, 16[27.54 9.222 (20-25)0.001LAS rest, 16[27.54 9.222 (20-25)0.001LAS rest, 16[130 (116-142)130 (115-143,00.10LAS rest, 16[130 (116-142)130 (115-143,00.10DBP strest, mmHg130 (116-142)130 (115-143,00.000LAD flow rest /n=469), cm/s85 (7-90,00.0010.002LDS strest, mmHg103 (116-142)105 (10-100,00.002LDS strest, mmHg130 (116-142)105 (10-100,00.002LDS strest, mmHg103 (116-142)105 (10-100,00.001LDS strest, 16185 (7-90,00.0010.001LDS stres	Prior PCI	26%	18%	0.006
HR rest, beats/min70 (62-78)70 (62-78)0.009SBP rest, mmHg130 (118-145)128 (120-138)0.009SBP rest, mmHg80 (70-90)80 (70-96)0.2026IMM, g/m²0.01 (76.4-107.6)89.6 (74.2-109.8)0.909RWT0.42 (0.37-0.48)0.38 (0.37-0.49)0.901e'rest, cm/s89 (74-10.5)95 (76-11.5)0.0001e'rest, cm/s89 (74-10.5)83 (65-10.4)83 (65-10.4)0.0010E/e'rest83 (65-10.4)83 (65-10.4)0.022.60.0001UESV rest, ml34 (26-50)0.024.40)0.00010.266GLS LV rest, fish1.06 (1.00-1.06)1.00 (1.00-1.00)0.266GLS LV rest, fish1.02 (1.00-1.06)1.00 (1.00-1.00)0.266GLS LV rest, fish1.22 (1.42-2.0)1.01 (1.41-19.2)0.010LAV rest, mt/m²28 (2.2-35)28 (2.2-36)0.090LAV rest, mt/m²28 (2.2-35)0.0210.010LAV rest, mmHg0.61-120 (1.51-142)0.010SP stress, mmHg1.30 (1.51-142)0.0100.022LDS dow rest (n=469), cm/s25 (2-37)0.0010.001SP stress, mmHg1.73 (15-195)1.76 (158-194)0.400DES stress, mmHg1.06 (2-132)0.0100.022LDES stress, mmHg26 (2-103)0.02010.001LDES stress, mmHg26 (2-103)0.0210.001LDES stress, fish0.002 (2.132)0.0100.010LDES stress, fish0.002 (2.132) <td< td=""><td>Dyspnea NYHA Class</td><td>2 (1-2)</td><td>1 (1-2)</td><td>0.0006</td></td<>	Dyspnea NYHA Class	2 (1-2)	1 (1-2)	0.0006
SBP rest, mmHg130 (118-145)128 (120-138)0.009DBP rest, mmHg80 (70-90)80 (70-86)0.026MM, g/m²90.1 (764-107.6)80 (674-109.8)0.939RVT0.42 (037-0.48)0.43 (037-0.49)0.901e'rest, cm/s70 (58-84)75 (3-89)0.001e'rest, cm/s81 (65-10.4)83 (65-10.2)0.670E'rest, cm/s83 (65-10.4)83 (65-10.2)0.001LVEF at rest, %61.6 (56-46.6.7)80 (24-40)0.001LVEF at rest, %61.6 (56-46.6.7)63.7 (S1-16.7)0.002LVEF at rest, %100 (1.00-1.06)1.00 (1.00-1.00)0.266GI S LV rest, MI7.2 (1.40-2.00)1.70 (1.45-19.2)0.011LAST rest, PM23 (22-37)2.202-25)0.0011LAST rest, PM23 (21-37)2.202-25)0.0011LAST rest, PM23 (21-31)7.717.71LAD flow rest (n=469), cm/s25 (21-31)0.721LAD flow rest (n=469), cm/s25 (21-31)0.71BP stress, mmHg85 (55-109)100 (1.00-1.00)0.262LDS stress, mmHg85 (55-109)9.080010.021LVES stress, mL0.012, 1.830.1640.0240.021LVES stress, mL0.013, 1.163, 1.10, 0.1640.1640.262LVES stress, mL0.014, 1.1630.1640.164LVES stress, mL0.016, 1.1830.1640.164LVES stress, mL0.016, 1.1830.1640.164LVES stress, MA0.024-1.10, 0.016 <td>HR rest, beats/min</td> <td>70 (62-78)</td> <td>70 (62-78)</td> <td>0.906</td>	HR rest, beats/min	70 (62-78)	70 (62-78)	0.906
DBP rest, mmlig 80 (70-90) 80 (70-86) 0.026 MM, g/m ² 901 (76.4-107.6) 89 (74-109.8) 0.399 RWT 0.42 (0.37-0.48) 0.43 (0.37-0.49) 0.098 f rest, cm/s 89 (74-10.5) 9.5 (7.6-11.5) 0.002 f rest, cm/s 89 (74-10.5) 9.5 (7.6-11.5) 0.002 E/e'rest 83 (65-10.4) 83 (65-10.2) 0.670 UKEDV rest, ml 94 (76-50) 30 (24-40) 0.0001 UKEDV rest, ml 1.00 (1.00-1.06) 1.00 (1.00-1.00) 0.266 G[S LV rest, [%] 1.7 (140-20.0) 1.70 (145-19.2) 0.410 VMSI rest 1.00 (1.00-1.06) 1.00 (1.00-1.00) 0.266 G[S LV rest, [%] 1.7 (140-20.0) 1.70 (145-19.2) 0.410 LAV_rest, m/m ² 2.8 (22-35) 2.8 (22-36) 0.890 LAV rest, m/m ² 8.8 (2-131) 2.6 (1-31) 0.791 B-Ines at rest, number 0.001 0.62 0.225 HR stress, beats/min 36 (16-109) 0.001 0.26 LVESV stress,	SBP rest, mmHg	130 (118-145)	128 (120-138)	0.009
IMM, g/m ² 90,1 (76,4-107,6) 896 (742-109,8) 0.599 RVT 0,42 (0,37-0,48) 0,43 (0,37-0,49) 0.008 E rest, cnv/s 70 (58-80) 75 (63-89) 0.0001 E/e/test 83 (6,5-104) 83 (6,5-102) 0.670 LVEDV rest, ml 94 (75-123) 85 (58-107) 0.0001 LVESV rest, ml 34 (26-50) 30 (24-40) 0.0001 LVESV rest, ml 1.00 (1.00-106) 1.00 (1.00-1.00) 0.266 GLS LV rest, MS 75 (41-40-2.00) 1.70 (14.5-19.2) 0.410 TAPSE rest, mm 23 (21-27) 22 (20-25) 0.0001 LAVL rest, MS 25 (21-31) 25 (21-31) 0.791 B-Ines at rest, number 0 (0-1) 0 (0-2) 0.025 LAVL rest, mLMP ² 26 (21-31) 25 (21-31) 0.791 B-Ines at rest, number 0 (0-1) 0 (0-2) 0.025 LAS rest, mLMP 25 (1-31) 0.701 0.701 B-B rest, mIM1g 130 (116-142) 10 (15-143) 0.610 D-B Verest, mLMP <	DBP rest, mmHg	80 (70-90)	80 (70-86)	0.026
RWT 0.42 (0.37-0.48) 0.43 (0.37-0.49) 0.098 Erest, cm/s 70 (58-84) 75 (63-89) 0.0001 e' rest, cm/s 83 (65-10.4) 8.3 (65-10.2) 0.670 LVEDV rest, ml 94 (75-123) 85 (58-107) 0.0001 LVEDV rest, ml 94 (75-123) 85 (58-107) 0.0001 LVET strest, % 616 (56.466.7) 63.27 (58.1-67.9) 0.0001 LVET strest, % 1.00 (1.00-1.05) 1.00 (1.00-1.00) 0.266 GLS LV rest, [%] 7.2 (1.40-20.0) 1.7 (1.45-19.2) 0.401 LASF rest, [%] 2.3 (21-27) 2.2 (20-2) 0.0001 LASF rest, [%] 2.5 (21-31) 2.791 0.894 LAV_rest, ml/m2 2.8 (22-35) 2.8 (22-36) 0.890 LAD flow rest (n=-469), cm/s 2.5 (21-31) 0.791 0.791 B-lines at rest, number 100 (11-42) 130 (115-143) 0.610 SBP stress, ml-g 85 (65-109) 80 (65-100) 0.0001 LVEDV stress, ml-g 2.6 (18-39) 2.6 (18-39) 0.0101	IMM, g/m ²	90.1 (76.4-107.6)	89.6 (74.2-109.8)	0.599
Erest, cm/s 75 (63-89) 75 (63-89) 0.0001 e'rest, cm/s 89 (74-10.5) 95 (7.6-11.5) 0.002 E/e'rest 83 (6.5-10.4) 83 (6.5-10.2) 0.0001 LVEDV rest, ml 94 (26-50) 85 (58-10.7) 0.0001 LVEDV rest, ml 34 (26-50) 30 (24-40) 0.0001 LVET arest, % 61.6 (56.466.7) 63.7 (8.1-67.9) 0.002 WMSI rest 1.00 (1.00-1.06) 1.00 (1.00-1.00) 0.66 GLS LV rest, l%[1.22 (1.4-2.0.0) 17.0 (1.45-19.2) 0.410 TAPSE rest, mm 23 (21-27) 22 (20-25) 0.0001 LAV_rest (n=/469), cm/s 25 (21-31) 276 9.36 LAV_rest (n=/469), cm/s 25 (21-31) 0.791 9.116 1.00 LAD flow rest (n=-469), cm/s 25 (21-31) 0.610 0.025 HR stress, beats/min 130 (116-142) 130 (115-143) 0.610 DSP stress, ml 85 (65-109) 0.800-990 0.0001 LVEDV stress, ml 85 (65-109) 80 (69-100.1 0.026	RWT	0.42 (0.37-0.48)	0.43 (0.37-0.49)	0.098
e'rest, cm/s 8.9 (7.4·10.5) 9.5 (7.6·11.5) 0.002 E/e'rest 8.3 (6.5·10.4) 8.3 (6.5·10.2) 0.670 LVEDV rest, ml 9.4 (7.5·12.3) 8.5 (8-10.7) 0.0001 LVESV rest, ml 4.2 (6-50) 3.0 (24-40) 0.0001 LVEST rest, % 1.00 (1.00-1.06) 1.00 (1.00-1.00) 0.266 GLS LV rest, %[6] 1.72 (1.40-20.0) 1.70 (1.45-19.2) 0.0001 LASF rest, [%] 27.5±9.2 27.6±9.3 0.894 LAV.rest, ml/m ² 28 (22-35) 28 (22-36) 0.890 LAD flow rest (n=469), cm/s 25 (21-31) 25 (21-31) 0.102 Bilnes at rest, number 0.001 0.002 0.025 HR stress, beats/min 130 (116-142) 130 (115-143) 0.610 SP stress, mmHg 57.2°9.0 90 (80-99) 0.001 UEDV stress, ml 85 (72-96) 90 (80-99) 0.001 LVESV stress, ml 26 (18-39) 25 (19-34) 0.247 E stress, cm/s 10.0 (82-118) 105 (90-120) 0.001	E rest, cm/s	70 (58-84)	75 (63-89)	0.0001
E/e 83 (65-10.4) 83 (65-10.2) 0.670 LVEDV rest, ml 94 (75-123) 85 (58-107) 0.0001 LVESV rest, ml 34 (26-50) 30 (24-40) 0.0001 LVESV rest, ml 34 (26-50) 30 (24-40) 0.0001 LVEST rest, % 1.00 (1.00-1.06) 1.00 (1.00-1.00) 0.266 GLS LV rest, % 1.00 (1.00-1.06) 1.00 (1.00-1.00) 0.266 GLS LV rest, [%] 7.2 (140-20.0) 17.0 (14.5-19.2) 0.410 TAPSE rest, mn 23 (21-27) 22 (20-25) 0.0001 LAV rest, m/m ² 28 (22-35) 28 (22-36) 0.890 LAV rest, m/m ² 28 (22-35) 28 (22-36) 0.890 LAV rest, m/m ² 28 (22-35) 28 (22-36) 0.890 LAV flow rest (n = 469), cm/s 25 (21-31) 0.610 0.25 BP stress, mlm ¹ g 130 (116-142) 10 (115-143) 0.610 DSP stress, mmHg 130 (116-142) 10 (0001 0.266 VESV stress, ml 26 (18-39) 20 (19-34) 0.277 Stress, mmH	e' rest. cm/s	8.9 (7.4-10.5)	9.5 (7.6-11.5)	0.002
VEDV rest, ml 94 (75-123) 85 (58-107) 0.0001 LVEDV rest, ml 34 (26-50) 30 (24-40) 0.0001 LVET artest, % 61.6 (564-667) 63.7 (58.1-67.9) 0.002 WMSI rest 1.00 (1.00-1.06) 1.00 (1.00-1.00) 0.266 GLS LV rest, [%] 1.72 (14.0-20.0) 1.70 (14.5-19.2) 0.410 TAPSE rest, mm 23 (21-27) 22 (20-25) 0.0001 LAVr, rest, [%] 27,5±9.2 27,6±9.3 0.894 LAVr, rest, ml/m ² 28 (22-35) 28 (22-36) 0.890 LAD flow rest (n=469), cm/s 25 (21-31) 0.791 0.791 B-lines at rest, number 0 (0-1) 0 (0-2) 0.025 HR stress, beats/min 130 (116-142) 130 (115-143) 0.610 SP stress, mmHg 85 (25-60) 90 (80-99) 0.0001 LVEDV stress, ml 85 (65-109) 80 (65-100) 0.026 LVEDV stress, ml 26 (18-39) 25 (19-34) 0.247 E stress, cm/s 100 (82 -118) 0.5 (90-120) 0.0001 <td< td=""><td>E/e' rest</td><td>8.3 (6.5-10.4)</td><td>8.3 (6.5-10.2)</td><td>0.670</td></td<>	E/e' rest	8.3 (6.5-10.4)	8.3 (6.5-10.2)	0.670
LVESV rest, ml 34 (26-50) 30 (24-40) 0,0001 LVEF at rest, % 616 (56.4-66.7) 63.7 (58.1-67.9) 0,002 WMSI rest 1.00 (1.00-1.06) 1.00 (1.00-1.00) 0,266 GLS LV rest, [%] 17.2 (14.0-20.0) 17.0 (14.5-19.2) 0,410 TAPSE rest, mm 23 (21-27) 22 (20-25) 0,0001 LAS rest, [%] 27.5 ± 9.2 27.6 ± 9.3 0,899 LAV (rest, m/m² 28 (22-35) 28 (22-36) 0,890 LAD flow rest (n = 469), cm/s 25 (21-31) 20 (0-2) 0,025 H Stress, beats/min 130 (116-142) 130 (115-143) 0,610 SBP stress, mmHg 173 (155-195) 176 (158-194) 0,418 DBP stress, mmHg 85 (65-109) 80 (65-100) 0,026 VESV stress, ml 26 (18-39) 25 (19-34) 0,247 E stress, cm/s 10 (08 (2-118) 105 (90-120) 0,0001 VESV stress, ml 28 (24-31) 25 (22-29) 0,0001 LVESV stress, % 291 ± 10.7 294 ± 10.4 0,251	LVEDV rest, ml	94 (75-123)	85 (58-107)	0.0001
LVEF at rest, % 61.6 (56.4-66.7) 63.7 (58.1-67.9) 0.002 WMSI rest 1.00 (1.00-1.06) 1.00 (1.00-1.00) 0.266 GLS LV rest, [%] 17.2 (14.0-20.0) 17.0 (14.5-19.2) 0.0001 TAPSE rest, mm 23 (21-27) 22 (20-25) 0.0001 LASr rest, [%] 27.5 ± 9.2 27.6 ± 9.3 0.890 LAV rest, m1/m ² 28 (22-35) 28 (22-36) 0.890 LAD flow rest (n=469), cm/s 25 (21-31) 0.60-1 0.60-2 0.025 HR stress, beats/min 130 (116-142) 130 (115-143) 0.610 SBP stress, mmHg 173 (155-195) 90 (80-99) 0.0001 LVEDV stress, ml 26 (18-39) 25 (19-34) 0.247 E stress, cm/s 100 (82-118) 105 (90-120) 0.0001 véstress, ml 28 (24-31) 25 (22-9) 0.0001 LAST stress, % 29.1 ± 10.7 29.9 ± 10.4 0.251 LAV stress, m1/m ² 28.3 (21.1-38.0) 27.7 (22.4-36.0) 0.990 GLS LV stress, [%] 10.0 (1.0-2.5) 10.0 (1.0-1.19)	LVESV rest. ml	34 (26-50)	30 (24-40)	0.0001
WMSI rest 1.00 (1.00-1.06) 1.00 (1.00-1.00) 0.266 GLS LV rest, [%] 17.2 (14.0-20.0) 17.0 (14.5-19.2) 0.410 TAPSE rest, mm 23 (21-27) 22 (20-25) 0.0001 LAS rest, [%] 27.5 ± 9.2 27.6 ± 9.3 0.894 LAVI_rest, ml/m ² 28 (22-35) 28 (22-36) 0.894 LAVI_rest, ml/m ² 28 (22-35) 28 (22-36) 0.894 LAVI_rest, ml/m ² 28 (21-31) 25 (21-31) 0.791 B-lines at rest, number 0 (0-1) 0 (0-2) 0.025 HR stress, beats/min 130 (116-142) 130 (115-143) 0.610 SBP stress, mmHg 57 (72-96) 90 (80-99) 0.0001 LVEDV stress, ml 26 (18-39) 25 (19-34) 0.247 E stress, cm/s 100 (82-118) 105 (90-120) 0.0001 LVESV stress, ml 28 (24-31) 25 (22-29) 0.0001 LAS ress, cm/s 10.10, (82-118,2) 1.5 (95-140,1) 0.990 LAS ttress, mm 28 (24-31) 25 (22-29) 0.0001	LVEF at rest. %	61.6 (56.4-66.7)	63.7 (58.1-67.9)	0.002
GL S LV rest, [%] 17.2 (14.0-20.0) 17.0 (14.5-19.2) 0.410 TAPSE rest, mm 23 (21-27) 22 (20-25) 0.0001 LAS rest, [%] 27.5 ± 9.2 27.6 ± 9.3 0.894 LAV_rest, ml/m ² 28 (22-35) 28 (22-36) 0.890 LAD flow rest (n=469), cm/s 25 (21-31) 25 (21-31) 0.791 B-lines at rest, number 0 (0-1) 0 (0-2) 0.025 R stress, beats/min 130 (116-142) 130 (115-143) 0.610 SBP stress, mmHg 173 (155-195) 176 (158-194) 0.418 DBP stress, mmHg 66 (65-109) 80 (65-100) 0.026 LVESV stress, ml 26 (18-39) 25 (19-34) 0.247 E stress, cm/s 100 (82-118) 105 (90-120) 0.0001 VESV stress, ml 28 (24-31) 25 (22-29) 0.0001 LAF stress, % 29.1 ± 10.7 29.9 ± 10.4 0.251 LAV stress, ml/m ² 28.3 (21-38.0) 27.7 (22-436.0) 0.990 GLS LV stress, ml/m ² 28.3 (21-38.0) 27.7 (22-436.0) 0.991 </td <td>WMSI rest</td> <td>1.00 (1.00-1.06)</td> <td>1.00 (1.00-1.00)</td> <td>0.266</td>	WMSI rest	1.00 (1.00-1.06)	1.00 (1.00-1.00)	0.266
TAPSE rest, nm23 (21-27)22 (20-25)0.0001LAS rrest, % 27.5 ± 9.227.6 ± 9.30.894LAVi_rest, nl/m228 (22-35)28 (22-36)0.890LAD flow rest (n = 469), cm/s25 (21-31)25 (21-31)0.791B-lines at rest, number0 (0-1)0 (0-2)0.025HR stress, beats/min130 (116-142)130 (115-143)0.610SBP stress, nmHg85 (72-96)90 (80-99)0.0001DED stress, mHg85 (65-109)80 (65-100)0.026LVEDV stress, ml26 (18-39)25 (19-34)0.247E stress, cm/s100 (82-118)105 (90-120)0.0001c'stress, cm/s11.5 (9.5-13.2)11.5 (9.5-14.0)0.060E/stress, m/m28 (24-31)25 (22-29)0.0001LAS stress, %29.1 ± 10.729.9 ± 10.40.251LAV stress, ml/m228.3 (21.1-38.0)7.7 (22.4-36.0)0.996GLS LV stress, %68.0 (60.2-74.5)68.4 (61.1-73.8)0.964WMSI stress, nuit10. (1.00-1.25)10. (1.00-1.19)0.132LAD flow stress (n= 428), cm/s50.0 (39.8-62.3)54.0 (42.0-63.0)0.287B-lines stress, number10.320.038-62.3)54.0 (42.0-63.0)0.287B-lines stress, number10.0 (0-0.17)0.1640.123U/C ontractile reserve1.78 (13.8-2.23)1.69 (1.33.2-12)0.063	GLSTV rest. 1%	17.2 (14.0-20.0)	17.0 (14.5-19.2)	0.410
LAS rest, 1%275 ± 9.2276 ± 9.30.894LAVi_rest, ml/m228 (22-35)28 (22-36)0.890LAD flow rest (n=469), cm/s25 (21-31)0.791B-lines at rest, number0 (0-1)0 (0-2)0.025HR stress, beats/min130 (116-142)130 (115-143)0.610SBP stress, mmHg173 (155-195)176 (158-194)0.418DBP stress, mmHg85 (65-109)80 (66-100)0.026LVEDV stress, ml26 (18-39)25 (19-34)0.247E stress, cm/s100 (82-118)105 (90-120)0.0001e'stress, cm/s11.5 (95-13.2)11.5 (95-14.0)0.060E/e'stress87 (6.9-10.7)88 (7.3-11.0)0.164TAS's stress, ml/m228 (24-31)25 (22-9)0.0001LAS's stress, ml/m2283 (21.1-38.0)27.7 (22.4-36.0)0.996UVES stress, ml/m2283 (21.1-38.0)27.7 (22.4-36.0)0.996UVE stress, ml/m268.0 (60.2-74.5)68.4 (61.1-73.8)0.964UVS stress, l%10.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress, number1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress, number1.0 (3.9-6.2.3)54.0 (4.2-6.3.0)2.87B-lines stress, number1.0 (3.9-6.2.3)54.0 (4.2-6.3.0)2.87B-lines stress, number1.0 (3.9-6.2.3)54.0 (4.2-6.3.0)2.87B-lines stress, number1.0 (3.9-6.2.3)54.0 (4.2-6.3.0)2.87B-lines stress, number1.0 (3.9-6.2.3)54.0 (4.2-6.3.0)	TAPSE rest. mm	23 (21-27)	22 (20-25)	0.0001
LAM_rest, ml/m228 (22-35)28 (22-36)0.890LAD_flow rest (n=469), cm/s25 (21-31)0.791B-lines at rest, number0 (0-1)0 (0-2)0.025HR stress, beats/min130 (116-142)130 (115-143)0.610SBP stress, mmHg173 (155-195)176 (158-194)0.418DBP stress, mmHg85 (72-96)90 (80-99)0.0001LVEDV stress, ml85 (65-109)80 (65-100)0.026LVESV stress, ml26 (18-39)25 (19-34)0.247E stress, cm/s100 (82 -118)105 (90 -120)0.0001e' stress, cm/s11.5 (95-13.2)11.5 (95-14.0)0.0001e' stress, cm/s11.5 (95-13.2)11.5 (95-14.0)0.0001LAS stress, %29.1 ± 10.729.9 ± 10.40.251LAV stress, ml/m228.3 (21.1-38.0)27.7 (22.4-36.0)0.990GLS LV stress, [%]1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress (n=428), cm/s50.0 (39.8-62.3)54.0 (42.0-63.0)0.287B-lines stress, number1.0 (3.02-74.5)68.4 (61.1-73.8)0.964WMSI stress, unit1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress (n=428), cm/s50.0 (39.8-62.3)54.0 (42.0-63.0)0.287B-lines stress, number1.06-300.2971.56Schemia36%41%0.1230.0027Ischemia36%41%0.1230.063UV contractile reserve1.78 (1.38-2.23)1.69 (1.33-2.12)0.063 <td> ASr rest. % </td> <td>27.5+9.2</td> <td>27.6+9.3</td> <td>0.894</td>	ASr rest. %	27.5+9.2	27.6+9.3	0.894
LAD flow rest (n=469), cm/s25 (21-31)25 (21-31)(7.791)B-lines at rest, number0 (0-1)0 (0-2)0.025HR stress, beats/min130 (116-142)130 (115-143)0.610SBP stress, mmHg173 (155-195)176 (158-194)0.418DBP stress, mmHg85 (72-96)90 (80-99)0.0001LVEDV stress, ml85 (65-109)80 (65-100)0.026LVESV stress, ml26 (18-39)25 (19-34)0.247E stress, cm/s100 (82-118)105 (90-120)0.0001e' stress, cm/s11.5 (9.5-13.2)11.5 (9.5-14.0)0.006E/ e' stress, rm28 (24-31)25 (22-29)0.0001LAPSE stress, ml28 (24-31)25 (22-29)0.0001LAS stress, %29.1 ± 10.729.9 ± 10.40.251LAV stress, M/m ² 8.3 (1.1-38.0)27.7 (22.4-36.0)0.990GLS LV stress, MS68.0 (60.2-74.5)68.4 (61.1-73.8)0.964WMSI stress, unit1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress (n=428), cm/s500 (39.8-62.3)54.0 (42.0-63.0)0.287B-lines stress, number10.3320.0-17)0.0-0.180.027schemia36%41%0.1230.027schemia0.0-0.17)0.0-0.180.5780.0-0.17LV stress, 1.69 (1.33-2.12)0.6510.5780.0-0.17LV stress, 1.69 (1.33-2.12)0.6510.0-0.170.0-0.180.578	LAVi rest. ml/m ²	28 (22-35)	28 (22-36)	0.890
B-lines at rest, number0 (0-1)0 (0-2)0.025HR stress, beats/min130 (115-142)130 (115-143)0.610SBP stress, mmHg173 (155-195)176 (158-194)0.418DBP stress, mmHg85 (72-96)90 (80-99)0.0001LVEDV stress, ml85 (65-109)80 (65-100)0.026LVESV stress, ml26 (18-39)25 (19-34)0.247E stress, cm/s100 (82 -118)105 (90 -120)0.0001e'stress, cm/s11.5 (9.5-13.2)11.5 (9.5-14.0)0.060E/e'stress87 (6.9-10.7)8.8 (7.3-11.0)0.164TAPSE stress, mm28 (24-31)25 (22-29)0.0001LA's stress, %29.1 ± 10.729.9 ± 10.40.251LA's stress, %29.1 ± 10.729.9 ± 10.40.251LA's stress, [%]17.0 (14.0-20.0)17.4 (12.6-20.6)0.936LVE F stress, %68.0 (60.2-74.5)68.4 (61.1-73.8)0.964WMS1 stress, number1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress (n=428), cm/s50.0 (39.8-62.3)54.0 (42.0-63.0)0.277Ischemia36%41%0.123dWMS10.0-0.17)0.0-0.18)0.578LV contactile reserve1.78 (1.38-2.23)1.69 (1.33-2.12)0.665	AD flow rest ($n = 469$), cm/s	25 (21-31)	25 (21-31)	0.791
H Stress, beats/min130 (116-142)130 (115-143)0.610SBP stress, mmHg173 (155-195)176 (158-194)0.418DBP stress, mmHg85 (72-96)90 (80-99)0.0001LVEDV stress, ml85 (65-109)80 (65-100)0.026LVESV stress, ml26 (18-39)25 (19-34)0.247E stress, cm/s100 (82 -118)105 (90 -120)0.0001e'stress, cm/s11.5 (9.5-13.2)11.5 (9.5-14.0)0.060E/e'stress8.7 (6.9-10.7)8.8 (7.3-11.0)0.164TAPSE stress, mm28 (24-31)25 (22-29)0.0001LA's stress, %29.1 ± 10.729.9 ± 10.40.251LAV stress, m/m²28.3 (21.1-38.0)2.7.7 (22.4-36.0)0.990GLS LV stress, [%]17.0 (14.0-20.0)17.4 (12.6-20.6)0.936LVEF stress, wint1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress (ni = 428), cm/s500 (39.8-62.3)54.0 (42.0-63.0)0.287B-lines stress, number1 (0-3)2 (0-4)0.271Ischemia36%41%0.123UV contartile reserve1.78 (1.38-2.23)1.69 (1.33-2.12)0.063	B-lines at rest, number	0 (0-1)	0 (0-2)	0.025
BP stress, mmHg 173 (155-19) 176 (158-194) 0.418 DBP stress, mmHg 85 (72-96) 90 (80-99) 0.0001 LVEDV stress, ml 85 (65-109) 80 (65-100) 0.026 LVESV stress, ml 26 (18-39) 25 (19-34) 0.247 E stress, cm/s 100 (82-118) 105 (90-120) 0.0001 e'stress, cm/s 11.5 (9.5-13.2) 11.5 (9.5-14.0) 0.060 E/e'stress 87 (6.9-10.7) 88 (7.3-11.0) 0.164 TAPSE stress, mm 28 (24-31) 25 (22-29) 0.0001 LASr stress, % 29.1 ± 10.7 29.9 ± 10.4 0.251 LAVi stress, ml/m ² 28.3 (21.1-38.0) 27.7 (22.4-36.0) 0.990 GLS LV stress, [%] 17.0 (14.0-20.0) 17.4 (12.6-20.6) 0.936 LVEF stress, % 68.0 (60.2-74.5) 68.4 (61.1-73.8) 0.964 WMSI stress, unit 1.0 (1.00-1.25) 1.0 (1.00-1.19) 0.132 LAD flow stress (n=428), cm/s 50.0 (39.8-62.3) 54.0 (42.0-63.0) 0.287 B-lines stress, number 1 (0-3) 2 (0-4)	HR stress, beats/min	130 (116-142)	130 (115-143)	0.610
DBP stress, mHg 85 (72-96) 90 (80-99) 0.001 LVEDV stress, ml 85 (65-109) 80 (65-100) 0.226 LVESV stress, ml 26 (18-39) 25 (19-34) 0.247 E stress, cm/s 100 (82 - 118) 105 (90 - 120) 0.0001 e'stress, cm/s 11.5 (9.5-13.2) 11.5 (9.5-14.0) 0.060 E/e'stress 8.7 (6.9-10.7) 8.8 (7.3-11.0) 0.164 TAPSE stress, mm 28 (24-31) 25 (22-29) 0.0001 LAST stress, % 29.1 ± 10.7 29.9 ± 10.4 0.251 LAVi stress, ml/m ² 28.3 (21.1-38.0) 2.77 (22.4-36.0) 0.990 GLS LV stress, [%] 17.0 (14.0-20.0) 17.4 (12.6-20.6) 0.936 LVEF stress, % 68.0 (60.2-74.5) 68.4 (61.1-73.8) 0.964 WMSI stress, unit 1.0 (1.00-1.25) 1.0 (1.00-1.19) 0.132 LAD flow stress (n=428), cm/s 50.0 (39.8-62.3) 54.0 (42.0-63.0) 0.287 B-lines stress, number 1.0-3) 2 (0-4) 0.027 Ischemia 36% 41% 0.123	SBP stress, mmHa	173 (155-195)	176 (158-194)	0.418
LVEDV stress, ml B5 (65-109) B0 (65-100) 0.026 LVESV stress, ml 26 (18-39) 25 (19-34) 0.247 E stress, cm/s 100 (82 -118) 105 (90 -120) 0.0001 e' stress, cm/s 11.5 (9.5-13.2) 11.5 (9.5-14.0) 0.060 E/e'stress 8.7 (6.9-10.7) 8.8 (7.3-11.0) 0.164 TAPSE stress, mm 28 (24-31) 25 (22-29) 0.0001 LA's stress, % 29.1 ± 10.7 29.9 ± 10.4 0.251 LAY istress, ml/m ² 28.3 (21.1-38.0) 27.7 (22.4-36.0) 0.990 GL LV stress, [%] 17.0 (14.0-20.0) 17.4 (12.6-20.6) 0.936 LVEF stress, % 68.0 (60.2-74.5) 68.4 (61.1-73.8) 0.964 WMSI stress, unit 1.0 (1.00-1.25) 1.0 (1.00-1.19) 0.132 LAD flow stress (n=428), cm/s 50.0 (39.8-62.3) 54.0 (42.0-63.0) 0.287 B-lines stress, number 1 (0-3) 2 (0-4) 0.027 Ischemia 36% 41% 0.123 dWMSI 0 (0-0.17) 0 (0-0.18) 0.578	DBP stress, mmHa	85 (72-96)	90 (80-99)	0.0001
LVESV stress, ml26 (18-39)25 (19-34)0.247E stress, cm/s100 (82 -118)105 (90 -120)0.0001e' stress, cm/s11.5 (9.5-13.2)11.5 (9.5-14.0)0.060E/e'stress8.7 (6.9-10.7)8.8 (7.3-11.0)0.164TAPSE stress, mm28 (24-31)25 (22-29)0.0001LA's stress, %29.1 ± 10.729.9 ± 10.40.251LAVi stress, ml/m²28.3 (21.1-38.0)27.7 (22.4-36.0)0.990GLS LV stress, [%]17.0 (14.0-20.0)17.4 (12.6-20.6)0.936LVEF stress, %68.0 (60.2-74.5)68.4 (61.1-73.8)0.964WMSI stress, unit1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress (n=428), cm/s50.0 (39.8-62.3)54.0 (42.0-63.0)0.287B-lines stress, number1 (0-3)2 (0-4)0.027Ischemia36%41%0.123dWMSI0 (0-0.17)0 (0-0.18)0.578LV contractile reserve1.78 (1.38-2.23)1.69 (1.33-2.12)0.063	LVEDV stress. ml	85 (65-109)	80 (65-100)	0.026
E stress, cm/s 100 (82 - 118) 105 (90 - 120) 0.0001 e' stress, cm/s 11.5 (9.5 - 13.2) 11.5 (9.5 - 14.0) 0.060 E/e'stress 8.7 (6.9 - 10.7) 8.8 (7.3 - 11.0) 0.164 TAPSE stress, mm 28 (24-31) 25 (22-29) 0.0001 LAS' stress, % 29.1 ± 10.7 29.9 ± 10.4 0.251 LAVi stress, ml/m ² 28.3 (21.1 - 38.0) 27.7 (22.4 - 36.0) 0.990 GLS LV stress, [%] 17.0 (14.0 - 20.0) 17.4 (12.6 - 20.6) 0.936 LVEF stress, with 1.0 (1.00 - 1.25) 68.4 (61.1 - 73.8) 0.964 WMSI stress, unit 1.0 (1.00 - 1.25) 1.0 (1.00 - 1.19) 0.132 LAD flow stress (n = 428), cm/s 50.0 (39.8 - 62.3) 54.0 (42.0 - 63.0) 0.287 B-lines stress, number 1 (0 - 3) 2 (0 - 4) 0.277 Ischemia 36% 41% 0.123 dWMSI 0 (0 - 0.17) 0 (0 - 0.18) 0.578 LV contractile reserve 1.78 (1.38-2.23) 1.69 (1.33-2.12) 0.063	LVESV stress, ml	26 (18-39)	25 (19-34)	0.247
e' stress, cm/s 11.5 (9.5-13.2) 11.5 (9.5-14.0) 0.060 E/e'stress 8.7 (6.9-10.7) 8.8 (7.3-11.0) 0.164 TAPSE stress, mm 28 (24-31) 25 (22-29) 0.0001 LASr stress, % 29.1 ± 10.7 29.9 ± 10.4 0.251 LAVi stress, ml/m ² 28.3 (21.1-38.0) 27.7 (22.4-36.0) 0.990 GLS LV stress, [%] 17.0 (14.0-20.0) 17.4 (12.6-20.6) 0.936 LVEF stress, % 68.0 (60.2-74.5) 68.4 (61.1-73.8) 0.964 WMSI stress, unit 1.0 (1.00-1.25) 1.0 (1.00-1.19) 0.132 LAD flow stress (n=428), cm/s 50.0 (39.8-62.3) 54.0 (42.0-63.0) 0.287 B-lines stress, number 1 (0-3) 2 (0-4) 0.271 Ischemia 36% 41% 0.123 dWMSI 0 (0-0.17) 0 (0-0.18) 0.578 LV contractile reserve 1.78 (1.38-2.23) 1.69 (1.33-2.12) 0.063	E stress. cm/s	100 (82 -118)	105 (90 -120)	0.0001
E/e'stress8.7 (6.9-10.7)8.8 (7.3-11.0)0.164TAPSE stress, mm28 (24-31)25 (22-29)0.0001LASr stress, %29.1 ± 10.729.9 ± 10.40.251LAVi stress, ml/m²28.3 (21.1-38.0)27.7 (22.4-36.0)0.990GLS LV stress, [%]17.0 (14.0-20.0)17.4 (12.6-20.6)0.936LVEF stress, %68.0 (60.2-74.5)68.4 (61.1-73.8)0.964WMSI stress, unit1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress (n=428), cm/s50.0 (39.8-62.3)54.0 (42.0-63.0)0.287B-lines stress, number1 (0-3)2 (0-4)0.027Ischemia36%41%0.123dWMSI0 (0-0.17)0 (0-0.18)0.578LV contractile reserve1.78 (1.38-2.23)1.69 (1.33-2.12)0.063	e' stress, cm/s	11.5 (9.5-13.2)	11.5 (9.5-14.0)	0.060
TAPSE stress, mm28 (24-31)25 (22-29)0.0001LASr stress, %29.1 ± 10.729.9 ± 10.40.251LAVi stress, ml/m228.3 (21.1-38.0)27.7 (22.4-36.0)0.990GLS LV stress, [%]17.0 (14.0-20.0)17.4 (12.6-20.6)0.936LVEF stress, %68.0 (60.2-74.5)68.4 (61.1-73.8)0.964WMSI stress, unit1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress (n=428), cm/s50.0 (39.8-62.3)54.0 (42.0-63.0)0.287B-lines stress, number1 (0-3)2 (0-4)0.027Ischemia36%41%0.123dWMSI0 (0-0.17)0 (0-0.18)0.578LV contractile reserve1.78 (1.38-2.23)1.69 (1.33-2.12)0.063	E/e'stress	8.7 (6.9-10.7)	8.8 (7.3-11.0)	0.164
LASr stress, %29.1 ± 10.729.9 ± 10.40.251LAVi stress, ml/m²28.3 (21.1-38.0)27.7 (22.4-36.0)0.990GLS LV stress, % 17.0 (14.0-20.0)17.4 (12.6-20.6)0.936LVEF stress, %68.0 (60.2-74.5)68.4 (61.1-73.8)0.964WMSI stress, unit1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress (n=428), cm/s50.0 (39.8-62.3)54.0 (42.0-63.0)0.287B-lines stress, number1 (0-3)2 (0-4)0.027Ischemia36%41%0.123dWMSI0 (0-0.17)0 (0-0.18)0.578LV contractile reserve1.78 (1.38-2.23)1.69 (1.33-2.12)0.063	TAPSE stress, mm	28 (24-31)	25 (22-29)	0.0001
LAVi stress, ml/m²28.3 (21.1-38.0)27.7 (22.4-36.0)0.990GLS LV stress, % 17.0 (14.0-20.0)17.4 (12.6-20.6)0.936LVEF stress, %68.0 (60.2-74.5)68.4 (61.1-73.8)0.964WMSI stress, unit1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress (n=428), cm/s50.0 (39.8-62.3)54.0 (42.0-63.0)0.287B-lines stress, number1 (0-3)2 (0-4)0.027Ischemia36%41%0.123dWMSI0 (0-0.17)0 (0-0.18)0.578LV contractile reserve1.78 (1.38-2.23)1.69 (1.33-2.12)0.063	LASr stress. %	29.1 ± 10.7	29.9±10.4	0.251
GLS LV stress, % 17.0 (14.0-20.0)17.4 (12.6-20.6)0.936LVEF stress, %68.0 (60.2-74.5)68.4 (61.1-73.8)0.964WMSI stress, unit1.0 (1.00-1.25)1.0 (1.00-1.19)0.132LAD flow stress (n=428), cm/s50.0 (39.8-62.3)54.0 (42.0-63.0)0.287B-lines stress, number1 (0-3)2 (0-4)0.027Ischemia36%41%0.123dWMSI0 (0-0.17)0 (0-0.18)0.578LV contractile reserve1.78 (1.38-2.23)1.69 (1.33-2.12)0.063	I AVi stress, ml/m ²	28.3 (21.1-38.0)	27.7 (22.4-36.0)	0.990
LVEF stress, % 68.0 (60.2-74.5) 68.4 (61.1-73.8) 0.964 WMSI stress, unit 1.0 (1.00-1.25) 1.0 (1.00-1.19) 0.132 LAD flow stress (n=428), cm/s 50.0 (39.8-62.3) 54.0 (42.0-63.0) 0.287 B-lines stress, number 1 (0-3) 2 (0-4) 0.027 Ischemia 36% 41% 0.123 dWMSI 0 (0-0.17) 0 (0-0.18) 0.578 LV contractile reserve 1.78 (1.38-2.23) 1.69 (1.33-2.12) 0.063	GLSTV stress. [%]	17.0 (14.0-20.0)	17.4 (12.6-20.6)	0.936
WMSI stress, unit 1.0 (1.00-1.25) 1.0 (1.00-1.19) 0.132 LAD flow stress (n=428), cm/s 50.0 (39.8-62.3) 54.0 (42.0-63.0) 0.287 B-lines stress, number 1 (0-3) 2 (0-4) 0.027 Ischemia 36% 41% 0.123 dWMSI 0 (0-0.17) 0 (0-0.18) 0.578 LV contractile reserve 1.78 (1.38-2.23) 1.69 (1.33-2.12) 0.063	LVEF stress. %	68.0 (60.2-74.5)	68.4 (61.1-73.8)	0.964
LAD flow stress (n=428), cm/s 50.0 (39.8-62.3) 54.0 (42.0-63.0) 0.287 B-lines stress, number 1 (0-3) 2 (0-4) 0.027 Ischemia 36% 41% 0.123 dWMSI 0 (0-0.17) 0 (0-0.18) 0.578 LV contractile reserve 1.78 (1.38-2.23) 1.69 (1.33-2.12) 0.063	WMSI stress unit	10(100-125)	1 0 (1 00-1 19)	0.132
B-lines stress, number 1 (0-3) 2 (0-4) 0.027 Ischemia 36% 41% 0.123 dWMSI 0 (0-0.17) 0 (0-0.18) 0.578 LV contractile reserve 1.78 (1.38-2.23) 1.69 (1.33-2.12) 0.063	LAD flow stress ($n = 428$), cm/s	50.0 (39.8-62.3)	54.0 (42.0-63.0)	0.287
Ischemia 36% 41% 0.123 dWMSI 0 (0-0.17) 0 (0-0.18) 0.578 LV contractile reserve 1.78 (1.38-2.23) 1.69 (1.33-2.12) 0.063	B-lines stress, number	1 (0-3)	2 (0-4)	0.027
dWMSI 0 (0-0.17) 0 (0-0.18) 0.578 LV contractile reserve 1.78 (1.38-2.23) 1.69 (1.33-2.12) 0.063	Ischemia	36%	41%	0.123
LV contractile reserve 1.78 (1.38-2.23) 1.69 (1.33-2.12) 0.063	dWMSI	0 (0-0.17)	0 (0-0.18)	0.578
	LV contractile reserve	1.78 (1.38-2.23)	1.69 (1.33-2.12)	0.063

	Modeling group N=513	Verification group <i>N</i> =542	р
CFVR	2.02 (1.60-2.38)	2.08 (1.71-2.36)	0.181
HRR	1.82 (1.59-2.11)	1.81 (1.57-2.07)	0.502
Δ B-lines	0 (0-2)	0 (0-2)	0.285

Abbreviations: CFVR coronary flow velocity reserve, DBP diastolic blood pressure, GLS global longitudinal strain, HR heart rate, HRR heart rate reserve, IMM index of myocardial mass is this LVMI, left ventricular mass index, LAD left anterior descending artery, LAS left atrial strain, LAVi left atrial volume index, LV left ventricle, LVEF left ventricle ejection fraction, LVEDV left ventricle end-diastolic volume, LVESV left ventricle end systolic volume, LVMI left ventricular mass index, MI myocardial infarction, NS non-significant, PCI percutaneous coronary intervention, RWT relative wall thickness, SBP systolic blood pressure, TAPSE tricuspid annular plane systolic excursion, WMSI wall motion score index

hypertension. Resting TTE revealed higher LAVI and lower LASr values in patients with a history of PAF. Additionally, ESE demonstrated a diminished chronotropic, contractile response with more pronounced diastolic dysfunction of the LV, reduced right ventricular contractile reserve, and a lower atrial functional reserve in these patients compared to individuals without a history of PAF.

In the modeling group, a logistic regression formula was developed and subsequently validated in the independent verification group. Logistic regression, though useful, cannot be directly applied during tests due to its complex formula. Instead, Score9/Score7 offer a simpler, more immediate alternative during multiparameter stress echocardiography. The simplified scores was settled for the whole cohort. The primary hypothesis driving the study was that changes in the size and function of the remodeled LA would manifest at rest but sometimes only during ESE. The study confirmed this hypothesis by revealing significant differences in LAVi and LASr at rest and during ESE between groups with and without PAF, even when other clinical and echocardiographic characteristics were similar. Score 9 demonstrated high sensitivity with moderate specificity. We believe that emphasizing sensitivity is crucial for identifying patients with PAF who may require further examination, such as multi-day EKG monitoring.

The findings demonstrated that LAVi and LASr during ESE have additive value in identifying atrial dysfunction in PAF. Moreover, the inclusion of rest and stress parameters collectively provides a more informative approach to detecting atrial myopathy. Indeed, the simple score, which incorporates known parameters of LA size at rest along with age and contractile parameters of the LA during exercise, exhibited greater predictive power compared to relying solely on resting LAVI.

The main clinical implication is to offer a potential means to identify patients with PAF within the SR population, including those with asymptomatic/subclinical undiagnosed forms. Such identification could be instrumental in devising preventive strategies for strokes, especially considering that nearly 65% of patients with cryptogenic stroke are found to have atrial myopathy, with 25% of these cases attributed to asymptomatic AF, which carries a substantial risk of thromboembolism [17, 18]. Potentially, the study findings could provide valuable information on changes in atrial function, which may be useful for further examination and close follow-up of patients who do not experience noticeable arrhythmias.

Numerous previous studies have consistently demonstrated a connection between LA enlargement, decreased LASr at rest, and the presence of AF or stroke [3, 4, 18– 20]. In patients with SR, these studies have also revealed an association between progressive LA remodeling, as assessed through serial TTE, and the progression of AF over extended follow-up periods. Patients who eventually developed persistent AF were found to have higher LAVi, and lower LASr compared to those in the PAF group [19].

Recent pilot and multicenter studies have further expanded our understanding by demonstrating that patients with AF exhibit LA dilation along with reduced LASr at rest and during stress. Importantly, LASr fails to increase during ESE, and patients with PAF display higher values of E/e' during stress (Table 4), resembling those seen in individuals with heart failure, CCS, and symptomatic AF [21–23]. These studies have indicated that LA dysfunction progresses from SR to PAF and eventually to permanent AF, and it is associated with more significant LV systolic dysfunction, increased LV filling pressure, and pulmonary congestion. In contrast, the normal healthy cohort showed a significant increase in deformation without changes in atrial stiffness during maximum ESE [24].

While previous studies on the function of the LA during exercise, using LASr, have been conducted in relatively small groups of 177 and 252 patients [5, 22], the current study was designed to comprehensively assess signs of LA dysfunction in a large cohort of patients, excluding those with AF during the test. The current study was planned to compose signs of LA dysfunction in Table 2 Differences in clinic, echocardiography, and ESE parameters in patients with and without PAF among the modeling group

	Patients without PAF N=463	Patients with PAF <i>N</i> =50	p
Age, years	64.0±11.4	66.0±7.5	0.008
Body mass index, kg/m ²	27.9 (25.2-31.0)	28.3 (25.4-32.4)	0.445
Body surface area, m ²	1.93±0.21	2.0±0.25	0.04
Hypertension	73%	88%	0.033
Diabetes	19%	13%	0.331
Smoking	10%	12%	0.571
Obesity	33%	36%	0.769
Prior MI	22%	18%	0.667
Prior PCI	26%	20%	0.400
Dyspnea NYHA Class	2 (1-2)	2 (1-2)	0.601
HR rest, beats/min	70 (62-78)	71 (63-77)	0.874
SBP rest, mmHg	130 (118-145)	129 (120-140)	0.719
DBP rest, mmHg	80 (70-90)	80 (68-87)	0.726
IMM, g/m ²	83.3 (75.9-107.2)	95.2 (84.9-109.9)	0.114
RWT	0.42 (0.37-0.48)	0.41 (0.37-0.46)	0.591
E rest, cm/s	70 (58-84)	70 (58-99)	0.448
e'rest, cm/s	9.0 (7.4-10.5)	8.7 (7.5-9.9)	0.645
E/e' rest	8.3 (6.6-10.3)	7.7 (6.4-13.7)	0.499
GLS LV rest, %	17.0±3.9	17.0±3.6	0.948
TAPSE rest, mm	23 (21-27)	23 (19-27)	0.513
LASr rest, %	27.9±8.9	23.5±10.8	0.001
LAVi_rest, ml/m ²	27.2 (21.3-34.7)	35.0 (31-44.7)	0.0001
LAD flow rest, cm/s	25 (21-31)	28 (22-31)	0.483
LVEDV rest, ml	93 (75-122)	98 (80-135)	0.187
LVESV rest, ml	34 (26-49)	36 (27-58)	0.342
LVEF at rest, %	61.6 (56.4-66.5)	62.1 (57.4-67.6)	0.723
WMSI rest	1.00 (1.00-1.00)	1.00 (1.00-1.00)	0.277
B-lines at rest, number 4-region scan	0 (0-1)	1 (0-1)	0.210
HR stress, beats/min	130 (117-144)	125 (108-133)	0.003
SBP stress, mmHg	174 (155-195)	169(150 -190)	0.227
DBP stress, mmHg	84 (72-96)	87 (68-96)	0.842
LVEDV stress, ml	85 (65-108)	92 (65-124)	0.112
LVESV stress, ml	26 (18-39)	27 (18-44)	0.517
E stress, cm/s	100 (90-120)	112 (90-120)	0.02
e' stress, cm/s	11.5 (9.5-13.1)	11.4 (9.2-13.5)	0.775
E/e'stress	8.6 (6.8-10.7)	9.8 (8.1-11.1)	0.125
TAPSE stress, mm	28 (25-31)	26 (23-31)	0.261
LASr stress, %	29.6±10.6	23.3±10.0	0.002
LAVi stress, ml/m ²	27.6 (20.5-36.1)	35.1 (30.0-46.4)	0.0001
GLS LV stress, % , (n=222)	16.8±4.6	18.6±4.2	0.078
LVEF stress, %	67.7 (60.3-74.2)	69.8 (59.9-74.9)	0.835
WMSI stress, unit	1.00 (1.00-1.25)	1.00 (1.00-1.19)	0.326
LAD flow stress, cm/s	51 (40-63)	48 (35-54)	0.224
B-lines stress (number) 4-region scan	1 (0-3)	1 (0-3)	0.401
Ischemia	37%	27%	0.235
LV contractile reserve	1.79 (1.38-2.23)	1.79 (1.38-2.19)	0.665
CFVR (n = 153)	2.04 (1.60-2.42)	1.64 (1.42-1.94)	0.101
HRR	1.83 (1.61-2.12)	1.67 (1.50-1.93)	0.023
∆ B-lines	0 (0-2)	0 (0-1)	0.054

Abbreviations: CFVR coronary flow velocity reserve, DBP diastolic blood pressure, GLS global longitudinal strain, HR heart rate, HRR heart rate reserve, IMM index of myocardial mass is this LVMI, left ventricular mass index, LAD left anterior descending artery, LAS left atrial strain, LAVi left atrial volume index, LV left ventricle, LVEF left ventricle ejection fraction, LVEDV left ventricle end-diastolic volume, LVESV left ventricle end systolic volume, LVMI left ventricular mass index, MI myocardial infarction, NS non-significant, PCI percutaneous coronary intervention, RWT relative wall thickness, SBP systolic blood pressure, TAPSE tricuspid annular plane systolic excursion, WMSI wall motion score index

 Table 3
 Differences in left atrium parameters in patients with and without PAF history

Variables	SR, no PAF history N=935	SR, PAF history N=120	P- values
Rest LAVI	27.1 (21.7-34.7)	34.3 (26.0-43.0)	< 0.0001
Rest LASr	28.0 ± 9.0	23.9 ± 10.5	< 0.001
Stress LAVI	27.0 (21.0-35.9)	33.9 (28.0-43.9)	< 0.0001
Stress LASr	30.3 ± 10.3	24.0 ± 10.2	< 0.001

Abbreviations: LAVi left atrial volume index, LASr left atrial reservoir strain

 Table 4
 Coefficients and Standard Errors in logistic regression analysis

Variable	Coefficient	Std. Error
Age	0.017290	0.02278
Rest LAVi	0.0066306	0.02054
Rest LASr	-0.072410	0.03444
Stress LAVi	0.047206	0.02543
Stress LASr	-0.0043906	0.02631
∆ B-lines during exercise	-0.16605	0.09263
Constant	-3.3053	

a large group, excluding patients with AF during the test, and further verification in the independent multicenter group in patients with heart failure and/or CCS.

In our study, we also noticed an increased E/e' value during ESE in the PAF group, consistent with higher LV filling pressures during ESE, a well-known consequence and cause of LA dysfunction when LA dilation exceeds



Fig. 2 Logistic regression analysis formula predictive value by ROC-analysis

Table 5	Cut-off values of the parameters for calculating the
score	

Variables	ROC-analysis cut-off value	SCORE
History of hypertension	yes	1
Rest LAVI	>31	1
Rest LASr	<23	1
Stress LAVI	> 29	1
Stress LASr	< 22	1
E/e' stress ($n = 609$)	>7	1
$\Delta TAPSE (n = 820)$	<5	1
HRR	< 1.64	1
LVCR	< 1.6	1
SCORE	>4	

Abbreviations: LAVi left atrial volume index, LASr left atrial reservoir strain, Δ -TAPSE difference between stress and rest tricuspid annular plane systolic excursion, HRR heart rate reserve, LVCR left ventricle contractile reserve

the range of LA Starling curve. This phenomenon is explained by atrial dysfunction, which can lead to exercise intolerance, as has been observed in previous studies [25, 26]. Additionally, the PAF group exhibited a reduced ability to achieve a higher heart rate during exercise, resulting in a smaller HRR, which is consistent with a reduced cardiac sympathetic reserve. Cardiac autonomic dysfunction is known to be a key player in the vulnerability to atrial arrhythmias, especially in the presence of LA dilation and reduced LA functional reserve.

Recognizing that some differences in echocardiographic parameters might be explained by age, the groups were matched by age. The main finding regarding differences



Fig. 3 Comparison of predictive values of LAVi at rest (in blue) and a composite score (in green) inclusive of age, rest LAVI, and stress LASr

 Table 6
 Differences in left atrium parameters in patients with and without PAF history in the matched groups

Variables	SR, no PAF history N=119	SR, PAF history N=119	P- values
Rest LAVI	27.9 (22.2-36.0)	34.3 (26.2-43.3)	< 0.001
Rest LASr	27.9±9.8	23.8 ± 10.5	< 0.01
Stress LAVI	30.0 (23.8-39.7)	34.0 (28.0-43.9)	< 0.006
Stress LASr	29.0 ± 9.8	23.8±10.2	< 0.001

Abbreviations: LAVi left atrial volume index, LASr left atrial reservoir strain

in LA sizes and function at rest and during stress tests between patients with and without PAF remained consistent. However, due to the relatively small sample sizes, some echocardiographic and stress echocardiography parameters might not have reached statistical significance.

Further studies are needed to explore the value of stress and rest indicators of LA dysfunction in groups without a known history of PAF. This could prove invaluable for the active diagnosis of possible asymptomatic AF, which is an essential step in identifying and managing this condition, especially considering its association with stroke risk [27, 28]. In addition, ongoing outcome studies will clarify whether patients with high vulnerability scores for AF but in SR at the time of study will develop episodes of PAF in the follow-up.

Study limitations

We did not divide patients with persistent and paroxysmal AF. The multicenter nature of the study allowed a multi-vendor assessment of LA function, but LASr may show some inter-vendor variability, although the adopted cutoff values for abnormality have been validated across different vendors and the inter-vendor variability does not apply to stress-rest variation, evaluated in the same patient with the same vendor.

Among LA strain parameters, only LASr was measured to simplify the method. We did not separately analyze the conduit and contractile phases, as LASr is more reproducible, easier to measure, and provides a better representation of the overall function of the LA. We focused on LASr, but right atrial strain can be even more important for detecting AF.

We only considered ESE, but similar patterns of normal responses of LAVI (with a slight increase or decrease during stress) and LASr (with an increase during stress) were observed during dobutamine and vasodilator stress echo [5, 29].

The study is among the largest with ESE in AF. A larger data set analyzed with artificial-intelligence using ECG [30] may be needed to optimize the prognostic potential of a combined anatomic and functional approach based on ESE.

Conclusion

ESE evaluation can be a valuable adjunct to rest LAVI and rest LASr for identifying patients in SR with history of PAF. Six different measures applied during ESE in patients with SR may help to identify those with prior PAF: LA contractile reserve with LASr, LA volume reserve with LAVI, LV contractile reserve with force, chronotropic reserve with HRR, right ventricular contractile reserve with Δ -TAPSE, and LV diastolic reserve with E/e'. This multifaceted approach identifies new spectrum of abnormal physiological responses to exercise detectable during ESE which can support understanding of symptoms and clinical management of individuals in SR, e.g. proactive monitoring programs to identify recurrences of AF and subsequent increase of cardiovascular risk.

Abbreviations

AF	Atrial fibrillation
CCS	Chronic coronary syndromes
ECG	Electrocardiogram
EF	Ejection fraction
ESE	Exercise stress echocardiography
HR	Hazard ratio
HRR	Heart rate reserve

- LA Left atrial
- LASr Left atrial strain of the reservoir phase
- LAVi Left atrial volume index
- LV Left ventricle
- PAF Paroxysmal-persistent atrial fibrillation
- RWMA Regional wall motion abnormality
- SR Sinus rhythm
- TAPSE Tricuspid annular plane systolic excursion
- TTE Transthoracic echocardiography
- 2DE Two-dimensional echocardiography
- WMSI Wall motion score index

Appendix: Stress echo 2030 study group

Jorge Lowenstein¹, Rosina Arbucci¹, Diego M. Lowenstein Haber¹, Sofia Marconi¹, Pablo M Merlo¹, Miguel Amor², Hugo Mosto², Michael Salamé², Patricia Carral², Germán Souto², Ariel Saad³, Caroline M. Van De Heyning⁴, Miodrag Ostojic⁵, Bojan Stanetic⁵, Tamara Kovačević Preradović⁵, Clarissa Borguezan-Daros⁶, Ana Cristina Camarozano⁷, Iana Simova⁸, Yi Wang⁹, Zhang Hongmei⁹, Ding Geqi⁹, Zhang Qingfeng¹⁰, Yue Heng Wang¹⁰, Albert Varga¹¹, Gergely Agoston¹¹, Attila Palinkas¹², Robert Sepp¹², Eszter D. Palinkas¹², Sergio Kobal¹³, Quirino Ciampi¹⁴, Bruno Villari¹⁴, Lauro Cortigiani¹⁵, Antonello D'Andrea¹⁶, Nicola Gaibazzi¹⁷, Domenico Tuttolomondo¹⁷, Elisa Merli¹⁸, Doralisa Morrone¹⁹, Fabio Mori²⁰, Maria Grazia D'Alfonso²⁰, Iacopo Olivotto²⁰, Annamaria Del Franco²⁰, Rodolfo Citro²¹, Rosangela Cocchia²², Eduardo Bossone²², Fausto Rigo²³, Francesca Bursi²⁴, Federica Re²⁵, Paolo Colonna²⁶, Ilaria Dentamaro²⁶, Marco Fabio Costantino²⁷, Fiorenzo Manganelli²⁸, Jelena Celutkiene²⁹, Hugo Rodriguez-Zanella³⁰, Karina Wierzbowska-Drabik³¹, Jaroslaw D. Kasprzak³², Maciej Haberka³³, Alla Boshchenko³⁴, Olga Zhuravleva³⁴, Natalia Sviazova³⁴ Tamara Ryabova³⁴, Ayten Safarova³⁵, Tatiana Timofeeva³⁵, Angela Zagatina³⁶, Elena Kalinina³⁶, Irina Begidova³⁶, Aleksandra Nikolic³⁷, Milica Dekleva³ Ana Djordievic-Dikic³⁹, Nikola Boskovic³⁹, Vojislav Giga³⁹, Milorad Tesic³⁹, Srdjan Dedic³⁹, Eugenio Picano³⁹, Jesus Peteiro Vazquez⁴⁰, Nithima Chaowalit Ratanasit⁴¹, Patricia A Pellikka⁴², Adelaide M. Arruda-Olson⁴², Ratnasari Padang⁴², Garvan C. Kane⁴², Hector R. Villarraga⁴², Ylenia Bartolacelli⁴³, Scipione Carerj⁴⁴, Mauro Pepi⁴⁵, Giovanni Benfari⁴⁶, Andrea Barbieri⁴⁷ 1 Cardiodiagnosticos, Investigaciones Medicas, Buenos Aires, Argentina 2 Hospital Echocardiography Laboratory, Ramos Mejia Hospital, Buenos Aires, Argentina

3 División de Cardiología, Hospital de Clínicas José de San Martín, Buenos Aires, Argentina:

4 Department of Cardiology, Antwerp University Hospital, 2650 Edegem, Belgium:

5 Clinic of Cardiovascular Diseases, University of Banja Luka University Clinical Centre of the Republic of Srpska

6 Cardiology Division, Hospital San José, Criciuma, Brasil

7 Hospital de Clinicas UFPR, Medicine Department, Federal University of Paranà, Curitiba, Brasil

8 Heart and Brain Center of Excellence, University Hospital, Pleven, Bulgaria 9 Department of Cardiovascular Ultrasound and Non-invasive Cardiology, Sichuan Provincial People's Hospital, China

10 Key laboratory of ultrasound in cardiac electrophysiology and biomechanics, The Affiliated Sichuan Provincial People's Hospital of Electronic Science and Technology University of China, Chengdu, China

11 Institute of Family Medicine, University of Szeged, Hungary

12 Second Department of Internal medicine and Cardiology Center, University Hospital, Szeged, Hungary, and Elisabeth Hospital, Internal Medicine Department, Hódmezővásárhely, Hungary

13 Echocardiography Unit, Soroka University Medical Center, Israele

14 Cardiology Division, Fatebenefratelli Hospital, Benevento, Italy

15 Cardiology Department, San Luca Hospital, Lucca, Italy

16 PO Umberto I°, Nocera Inferiore, ASL Salerno, Salerno, Italy

17 Cardiology Department, Parma University Hospital, Italy

18 Department of Cardiology, Ospedale per gli Infermi, Faenza, Ravenna, Italy 19 Cardiothoracic Department, University of Pisa, Italy

20 SOD Diagnostica Cardiovascolare, DAI Cardio-Toraco-Vascolare, e Cardiomyopathy unit, Azienda Ospedaliera-Universitaria Careggi, Italy

21 Cardiology Department and Echocardiography Lab, University Hospital "San Giovanni di Dio e Ruggi d'Aragona," Salerno, Italy

22 Azienda Ospedaliera Rilevanza Nazionale A. Cardarelli Hospital, Naples, Italy:

23 Villa Salus Foundation, IRCCS San Camillo Hospital, Venice, Italy

24 ASST Santi Paolo e Carlo. Presidio Ospedale San Paolo, Milano, Italy

25 Ospedale San Camillo, Cardiology Division, Rome, Italy

26 Cardiology Hospital, Policlinico University Hospital of Bari, Italy:

27 Cardiology Division, San Carlo Hospital, Potenza, Italy

28 Ospedale Moscati Avellino, Cardiology Division, Province of Avellino, Italy 29 Centre of Cardiology and Angiology, Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, State Research Institute Center for Innovative Medicine, LT-03101 Vilnius, Lithuania 30 Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico

31 Department of Internal Disease and Clinical Pharmacology, Lodz, Poland

32 Bieganski Hospital, Medical University, Lodz, Poland

33 University of Silesia, Cardiology Department, Katowice, Poland

34 Cardiology Research Institute, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Tomsk, Russian Federation

35 Department of Internal Medicine with a course in Cardiology and functional Diagnostics at the Medical Institute of the Peoples' Friendship University of Russia, Moscow, Russian Federation

36 Cardiology Department, Research Cardiology Center "Medika", Saint Petersburg, Russian Federation

37 Department of Noninvasive Cardiology, Institute for Cardiovascular Diseases Dedinje, School of Medicine, Belgrade, Serbia

38 Clinical Cardiology Department, Clinical Hospital Zvezdara, Medical School, University of Belgrade, Serbia

39 Cardiology Clinic, University Center Serbia, Medical School, University of Belgrade, Serbia

40 CHUAC- Complexo Hospitalario Universitario A Coruna- University of A Coruna, La Coruna, Spain

41 Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

42 Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA

43 Paediatric Cardiology and Adult Congenital Heart Disease Unit, S. Orsola-Malpighi Hospital, Bologna, Italy

44 Divisione di cardiologia, Policlinico Universitario, Università di Messina, Messina, Italy

45 Centro Cardiologico Monzino, IRCCS, Milan, Italy

46 University of Verona, Verona, Italy

47 Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Policlinico di Modena, University of Modena and Reggio Emilia, Italy

Authors' contributions

A.Z. originated idea, collected patients, prepared images and loops, and drafted the manuscript, Q.C. is the principal investigator of SE2030, collected patients, and drafted the manuscript, made the data quality control and contributed to data analysis, J.V.P. collected patients, E. K. collected patients, and drafted the manuscript, I. B. collected patients, prepared images and loops, and drafted the manuscript, R. P. collected patients, A. B. collected patients, E. M. collected patients, M. L. collected patients, H. R.-Z., S. K. collected patients, G.A. collected patients, A.V. collected patients, K.W.-D. collected patients, J. D. K. collected patients, R.A. collected patients, O. Z. collected patients, J. C. collected patients, J. L. collected patients, N. C. R. collected patients, P.A.P. served as the study co-chair, critically reviewed the protocol, helped to orient the data analysis, and critically revised the manuscript; E.P. served as the study chairman, designed the protocol, helped to orient the data analysis, and critically reviewed the manuscript; P. C., M.P. and S.C. are the Presidents and President-elect of the SIECVI, the scientific society that endorsed, organized, and funded the study. All authors contributed to the study design, undertook the quality control up to certification, critically revised the manuscript for an intellectually important contribution, and approved the submitted version.

Funding

Travel, publication, and infrastructural funding from Società Italiana di Ecocardiografia e Cardiovascular Imaging (SIECVI).

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Ethical approval and consent to participate

The study was managed and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients before inclusion. The study protocol was reviewed and approved by the institutional ethics committees, as a part of the more comprehensive stress echo 2020 study (148-Comitato Etico Lazio-1, July 16, 2016; Clinical trials.Gov Identifier NCT 030.49995) and stress echo 2030 study (291/294/295 Comitato Etico Lazio-1, March 8, 2021; Clinical trials.Gov Identifier NCT 050.81115).

Competing interests

The authors declare no competing interests.

Author details

¹Cardiology Department, Research Cardiocenter "Medika", St. Petersburg, Russian Federation.²Fatebenefratelli Hospital of Benevento, Benevento, Italy. ³CHUAC- Complexo Hospitalario Universitario A Coruna- University of A Coruna, La Coruna, Spain. ⁴Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. ⁵Cardiology Research Institute, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Tomsk, Russian Federation. ⁶Cardiology Unit, Ospedale Per Gli Infermi, Faenza, Italy. ⁷Department of Cardiovascular Disease, Division of Cardiology, AUSL Romagna, Ospedale S. Maria Delle Croci, Ravenna, Italy.⁸Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico.⁹Echocardiography Unit, Soroka University Medical Center, Be'er Sheva, Israel. ¹⁰Institute of Family Medicine, University of Szeged, Szeged, Hungary. ¹¹Department of Internal Disease and Clinical Pharmacology, Medical University, Lodz, Poland. ¹²First Department and Chair of Cardiology, Medical University of Lodz, Bieganski Specialty Hospital, Lodz, Poland. ¹³Investigaciones Medicas, Buenos Aires, Argentina. ¹⁴Centre of Cardiology and Angiology, Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Centre of Innovative Medicine, Vilnius, Lithuania. ¹⁵ Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. ¹⁶Department of Cardiology, Policlinico Hospital, Bari, Italy. ¹⁷Divisione Di Cardiologia, Policlinico UniversitarioUniversità Di Messina, Messina, Italy.¹⁸Centro Cardiologico Monzino, IRCCS, Milan, Italy.¹⁹Cardiology Clinic, University Center Serbia, Medical School, University of Belgrade, Belgrade, Serbia.

Received: 26 June 2024 Accepted: 23 September 2024 Published online: 04 November 2024

References

- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, ESC Scientific Document Group, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498.
- Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, ASSERT Investigators, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–9.
- Olsen FJ, Møgelvang R, Jensen GB, Jensen JS, Biering-Sørensen T. Relationship between left atrial functional measures and incident atrial fibrillation in the general population: the Copenhagen City heart study. JACC Cardiovasc Imaging. 2019;12:981–9.
- Hauser R, Nielsen AB, Skaarup KG, Lassen MCH, Duus LS, Johansen ND, Sengeløv M, Marott JL, Jensen G, Schnohr P, et al. Left atrial strain predicts incident atrial fibrillation in the general population: the Copenhagen City Heart Study. Eur Heart J Cardiovasc Imaging. 2021;23:52–60.
- Morrone D, Arbucci R, Wierzbowska-Drabik K, Ciampi Q, Peteiro J, Agoston G, Varga A, Camarozano AC, Boshchenko A, Ryabova T, et al. Feasibility and functional correlates of left atrial volume changes during stress echocardiography in chronic coronary syndromes. Int J Cardiovasc Imaging. 2021;37:953–64.
- Rausch K, Shiino K, Putrino A, Lam AK, Scalia GM, Chan J. Reproducibility of global left atrial strain and strain rate between novice and expert using multi-vendor analysis software. Int J Cardiovasc Imaging. 2019;35(3):419–26.
- Picano E, Ciampi Q, Citro R, D'Andrea A, Scali MC, Cortigiani L, Olivotto I, Mori F, Galderisi M, Costantino MF, et al. Stress echo 2020: the international stress echo study in ischemic and non-ischemic heart disease. Cardiovasc Ultrasound. 2017;15:3.
- Picano E, Ciampi Q, Cortigiani L, Arruda-Olson AM, Borguezan-Daros C, de Castro E Silva Pretto JL, Cocchia R, Bossone E, Merli E, Kane GC, et al. Stress Echo 2030: the Novel ABCDE-(FGLPR) protocol to define the future of imaging. J Clin Med. 2021;10:3641.
- Picano E, Ciampi Q, Arbucci R, Cortigiani L, Zagatina A, Celutkiene J, Bartolacelli Y, Kane GC, Lowenstein J, Pellikka P. Stress Echo 2030: the new ABCDE protocol defining the future of cardiac imaging. Eur Heart J Suppl. 2023;25(Suppl. C):C63–7.
- Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–70. Erratum in: Eur Heart J Cardiovasc Imaging. 2016;17:412. Erratum in: Eur Heart J Cardiovasc Imaging.
- Picano E, Zagatina A, Wierzbowska-Drabik K, BorguezanDaros C, D'Andrea A, Ciampi Q. Sustainability and versatility of the ABCDE protocol for stress echocardiography. J Clin Med. 2020;9:3184.
- Pellikka PA, Arruda-Olson A, Chaudhry FA, Chen MH, Marshall JE, Porter TR, Sawada SG. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the American Society of Echocardiography. J Am Soc Echocardiogr. 2020;33:1–41.
- Ciampi Q, Picano E, Paterni M, Daros CB, Simova I, de Castro E Silva Pretto JL, Scali MC, Gaibazzi N, Severino S, Djordjevic-Dikic A, et al. Quality control of regional wall motion analysis in stress Echo 2020. Int J Cardiol. 2017;249:479–85.
- Scali MC, Ciampi Q, Picano E, Bossone E, Ferrara F, Citro R, Colonna P, Costantino MF, Cortigiani L, Andrea A, et al. Quality control of B-lines analysis in stress Echo 2020. Cardiovasc Ultrasound. 2018;16:20.
- Picano E, Pierard L, Peteiro J, Djordjevic-Dikic A, Sade LE, Cortigiani L, Van De Heyning CM, Celutkiene J, Gaibazzi N, Ciampi Q, et al. The Clinical use of stress echocardiography in chronic coronary syndromes and beyond coronary artery disease: a clinical consensus statement from the European association of cardiovascular imaging of the ESC. Eur Heart J Cardiovasc Imaging. 2024;25:e65–90.
- Badano LP, Kolias Tj, Muraru D, Abraham Tp, Aurigemma G, Edvardsen T, D'Hooge J, Donal E, Fraser AG, Marwick T, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using

two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2018;9:591–600.

- Yaghi S, Boehme AK, Hazan R, Hod EA, Canaan A, Andrews HF, Kamel H, Marshall RS, Elkind MS. Atrial cardiopathy and cryptogenic stroke: a crosssectional pilot study. J Stroke Cerebrovasc Dis. 2016;25:110–4.
- Yaghi S, Kamel H, Elkind MSV. Atrial cardiopathy: a mechanism of cryptogenic stroke. Expert Rev Cardiovasc Ther. 2017;15:591–9.
- Leung M, van Rosendael PJ, van der Bijl P, Regeer MV, van Wijngaarden SE, Leung DY, Delgado V, Marsan NA, Ng ACT, Bax JJ. The value of serial echocardiography in risk assessment of patients with paroxysmal atrial fibrillation. Int J Cardiovasc Imaging. 2024;40:499–508.
- Maheshwari A, Norby FL, Inciardi RM, Wang W, Zhang MJ, Soliman EZ, Alonso A, Johansen MC, Gottesman RF, Solomon SD, et al. Left atrial mechanical dysfunction and the risk for ischemic stroke in people without prevalent atrial fibrillation or stroke: a prospective cohort study. Ann Intern Med. 2023;176:39–48.
- Ariyaratnam JP, Mishima RS, McNamee O, Emami M, Thiyagarajah A, Fitzgerald JL, Gallagher C, Sanders P, Elliott AD. Exercise echocardiography to assess left atrial function in patients with symptomatic AF. Int J Cardiol Heart Vasc. 2023;21(50):101324. https://doi.org/10.1016/j.ijcha.2023. 101324. PMID: 38204984.
- Zagatina A, Rivadeneira Ruiz M, Ciampi Q, Wierzbowska-Drabik K, Kasprzak J, Kalinina E, Begidova I, Peteiro J, Arbucci R, Marconi S, Stress Echo 2030 Study Group, et al. Rest and stress left atrial dysfunction in patients with atrial fibrillation. J Clin Med. 2023;12:5893.
- Wierzbowska-Drabik K, Kasprzak JD, Haberka M, Peteiro J, Re F, D'Alfonso MG, Mori F, Palinkas ED, Agoston G, Varga A, et al. Left atrial volume changes during exercise stress echocardiography in heart failure and hypertrophic cardiomyopathy. Hellenic J Cardiol. 2022;67:9–18.
- Romero Z, Arbucci R, Sevilla D, Rousse MG, Lowenstein D, Rodriguez I, Ugalde GN, Lowenstein J. The Reservoir Function. Functional evaluation of the left atrium by two-dimensional strain during rest and exercise stress. Rev Argentina Cardiol. 2017;85:520–6.
- Maffeis C, Rossi A, Cannata L, Zocco C, Belyavskiy E, Radhakrishnan AK, Feuerstein A, Morris DA, Pieske-Kraigher E, Pieske B, et al. Left atrial strain predicts exercise capacity in heart failure independently of left ventricular ejection fraction. Heart Fail. 2022;9:842–52.
- Zegkos T, Kamperidis V, Ntelios D, Gossios T, Parcharidou D, Tziomalos G, Papanastasiou CA, Boutou AK, Katranas S, Rouskas P, et al. Left atrial myopathy is associated with exercise incapacity and ventilatory inefficiency in hypertrophic cardiomyopathy. Heart Lung Circ. 2023;32:215–23.
- Gautier A, Picard F, Ducrocq G, Elbez Y, Fox KM, Ferrari R, Ford I, Tardif JC, Tendera M, Steg PG, CLARIFY investigators. New-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry. Eur Heart J. 2024;45:366–75.
- Hatala R, Hlivák P. Atrial fibrillation in chronic coronary syndromes: a neglected challenge. Eur Heart J. 2024;45:376–8.
- Prota C, Cortigiani L, Campagnano E, Wierzbowska-Drabik K, Kasprzak JD, Colonna P, Merli E, Manganelli F, Gaibazzi N, D'Andrea A, et al. Left atrial volume, function and B-lines during vasodilator stress echocardiography. Explor Cardiol. 2024;3:9–18.
- Yuan N, Duffy G, Dhruva SS, Oesterle A, Pellegrini CN, Theurer J, Vali M, Heidenreich PA, Keyhani S, Ouyang D. Deep learning of electrocardiograms in sinus rhythm from US veterans to predict atrial fibrillation. JAMA Cardiol. 2023;8:1131–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.